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CHAPTER I 
INTRODUCTION 
The overall objective of this dissertation study was 
to ascertain the effects in rats of peripherally adminis-
tered carboxylated 1,2,3,4-tetrahydroisoquinolines (THIQs) 
on the levels of biogenic amines in certain brain regions. 
Furthermore, the principal metabolic routes of specific car-
boxylated THIQs were elucidated, particularly whether decar-
boxylation was apparent. The central nervous system (CNS) 
uptake of the THIQs and their major metabolites were meas-
ured and related to changes in the levels of the bio- genic 
amines. 
A. Background: 
Condensation products derived from neurotransmitters 
and carbonyl compounds have been detected in the disease 
states of alcoholism (1,2), Parkinson's disease(3), and phe-
nylketonuria(4). Since endogenous levels of these condensa-
tion products have been reported, a new emphasis has been 
placed upon the pharmacology, origin, and metabolism of 
these compounds. 
1 
The condensation products can be separated into two 
main groups: the THIQs and the tetrahydro-beta-carbolines 
(THBCs). The THIQs are condensation products of phenethyla-
mines and carbonyl compounds. The THBCs are condensation 
products of indoleamines and carbonyl compounds. There are 
at least four basic sources of the carbonyl compounds which 
are available to condense with these neurotransmitters. The 
first source is acetaldehyde (AcH) which is derived from 
ethanol oxidation. A list of several AcH condensation prod-
ucts is found in Table 1. The second is formaldehyde which 
can come from methanol or from the tetrahydrofolate linked 
metabolism of one carbon fragments. Table 2 contains a list 
of these condensation products. The third source is pyruvic 
acid which is a normal product of glucose metabolism. The 
fourth source is an actual carbonyl metabolite of the neu-
roamine itself. Table 3 shows specific examples of this 
type of condensation product. 
B. The presence of condensation products in mammals. 
Acetaldehyde condensation products with dopamine (DA) 
and 1-Dopa are presented in Table 1. The dopamine and AcH 
condensation product, salsolinol (SAL), has been found to be 
in rat brain(S), human cerebrospinal fluid(6), adrenals(7), 
and urine(8). Its mono-a-methylated metabolite 
7-0-methyl-SAL (7-M-SAL) has been found in cerebrospinal 
2 
Parent Compound 
Dopamine 
3-0-Methyl-Dopa 
4-0-Methyl-Dopa 
Serotonin 
5-Methoxytryptamine 
Table 1 
ACETALDEHYDE CONDENSATION PRODUCTS 
Product 
1-Methyl-3-carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline 
(3-CSAL) 
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline 
(Salsolinol; Sal) 
1-Methyl-3-carboxy-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroiso-
quinoline (6M-3-CSAL) 
1-Methyl-3-carboxy-6-hydroxy-7-methoxy-1,2,3~4-tetrahydroiso­
quinoline (7M-3-CSAL) 
1-Methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline 
(1-Methyl-6-hydroxy-THBC) 
1-Methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline 
(1-Methyl-6-Methoxy-THBC) 
Table 2 
FORMALDEHYDE CONDENSATION PRODUCTS 
Parent Compound Product 
1-DOPA 3-Carboxy-norsalsolinol (3-Carboxy-6,7-dihydroxy-
tetrahydroisoquinoline) 
Dopamine Norsalsolinol (6,7-dihydroxy-tetrahydroisoquinoline) 
Serotonin 6-Hydroxy-tetrahydronorharmane 
5-Methoxytryptamine 6-Methoxy-tetrahydronorharmane 
Tetrahydropapaveroline Tetrahydroprotoberberine (THB) 
Parent Amine 
Dopamine 
Dopamine 
Dopamine 
Dopamine 
Table 3 
NEUROAMINE DERIVED CONDENSATION PRODUCTS 
Carbonyl Compound 
3,4,-dihydroxyphenylacetaldehyde 
3,4-dihydroxyphenylpyruvic acid 
Phenylacetaldehyde 
Phenylpyruvic acid 
Product 
Tetrahydropapaveroline (THP; 
norlaudanosoline) 
1-Carboxy-Tetrahydropapaveroline 
(1-Carboxy-THP) 
3',4'-desoxynorlaudanosoline 
3',4'-desoxynorlaudanosoline-1-
carboxylic acid (DNLCA) 
fluid (6). Large amounts of 7-M-SAL have been found in the 
urine of alcoholics undergoing detoxification(8). 
Barker et al (9) have reported whole rat brain levels 
of 6, 7 -dihydroxy-THIQ, the DA and formaldehyde adduct. It 
is speculated that one carbon groups linked to tetrahydrofo-
late or S-adenosyl methionine are the source of the formal-
dehyde for this condensation product. The condensation prod-
uct of DA and pyruvic acid is 1-carboxy-SAL (1-CSAL). The 
condensation product of 1-Dopa and AcH is 3-carboxy-SAL 
(3-CSAL) which is a geometric isomer of 1-CSAL. The THIQs 
derived from formaldehyde, AcH, or pyruvic acid are known as 
"simple" THIQs. 
"Complex" THIQs are derived from the condensation of 
catecholamines and catecholamine derived aldehydes. The 
product of the condensation of DA and 
3, 4-dihydroxyphenylacetaldehyde is tetrahydropapaveroline 
(THP), which is a probable intermediate in the synthesis of 
morphine by the poppy (10-14). The complex THIQ derived from 
DA and 3,4-dihydroxyphenylpyruvic acid is 1-carboxy-THP. 
THBC formation following ethanol intake has been 
reported by several investigators. Mcisaac (15) administered 
radiolabeled 5-methoxytryptamine and ethanol or AcH to rats 
which had been pretreated with iproniazid and disulfuram. He 
found the formation of urinary radio labeled 
6 
6-methoxy-1-methyl-1,2,3,4-THBC in the rats. Dajani and 
Saheb (16) administered 5-hydroxytryptophan and radiolabeled 
ethanol to rats that were treated with inhibitors of monoa-
mine oxidase (MAO) and aldehyde dehydrogenase inhibitors. 
Using thin-layer chromatography as a means of detection the 
researchers believe that they found 6-hydroxy-1-methyl-THBC 
in 24 hour urine samples from the treated rats. Dajani and 
Saheb failed to rule out the possibility that the spot iden-
tified was the formaldehyde adduct of serotonin, 
6-hydroxy-THBC, which has been demonstrated to be a normal 
constituent of platelets. Rommelspacher et al. (17) have 
shown that 6-hydroxy-THBC, th~ derivative of serotonin and 
formaldehyde is present in rat brain and platelets and is 
excreted by human volunteers ingesting 5-hydroxytryptophan 
(5-HTP). The condensation product of tryptamine and formal-
dehyde, THBC, has been found in platelet rich human plasma 
(18). Bidder et al (19) found material in human platelets 
which was characterized as 1-methyl-beta-carboline CHar-
mane), which is the fully aromatised beta-carboline. 
3-carboxy-harman has been found in the urine of cows which 
were fed silage (20). Evidence has been accumulating showing 
that THBC is a normal constituent of both rat brain and 
adrenals. The 6-methoxy congener of THBC is readily quanti-
fiable in rat adrenals (21). 
7 
In vitro THBC formation is much slower than 
6,7-dihydroxy-THIQ in the uncatalyzed process. However, the 
ratio of endogenous THBC to the 6, 7 -dihydroxy-THIQ in rat 
brain is orders of magnitude greater. This fact has lead 
Barker et al (22) to speculate that the formation of formal-
dehyde derived THBCs in brain is an enzyme related or cata-
lyzed process. The pyruvic acid derived beta-carbolines 
have not previously been described in the literature, but 
have been detected in a spinal fluid sample taken at death 
from a patient suffering from Leigh's disease (23) and in 
the spinal fluid of alcoholic monkeys (24). 
C. Overview of neuroamine synthesis and metabolism. 
The condensation products introduced thus far are 
derived from the neurotransmitters DA, norepinephrine (NE), 
and serotonin (5-HT). An overview of the substrates and 
enzymes involved in the syntheses and metabolism of these 
neurotransmitters is necessary for an understanding of the 
neuropharmacology and metabolism of these condensation prod-
ucts. 
Tyrosine is the essential dietary amino acid necessary 
for the synthesis of the catecholamines DA and NE. Tyrosine 
is hydroxylated by the enzyme tyrosine hydroxylase yielding 
the amino acid L-Dopa. L-Dopa is subsequently decarboxylated 
8 
by Dopa decarboxylase (DDC) which is also known as Aromatic 
Amino Acid Decarboxylase. The product of this reaction is 
the neurotransmitter DA. For dopaminergic neurons, this is 
the end point of the synthesis scheme. In noradrenergic neu-
rons DA is hydroxylated by the enzyme dopamine-beta-hydroxy-
lase to yield NE (Figure 1). 
The metabolism and clearance of DA is accomplished via 
the processes of oxidation, a-methylation, and/or conjuga-
tion. Dopamine is oxidized by the enzyme monoamine oxidase 
(MAO) to 3,4-dihydroxyphenylacetaldehyde (dopaldehyde). The 
oxidation of a biogenic amine to an acid is a two step pro-
cess with the enzyme monoamine oxidase (MAO) taking care of 
the first step. There are two known isozymes of MAO: MAO A 
and MAO B. The preferred substrates for MAO A are 5-HT and 
NE. Phenethylamine and benzylamine are the preferred sub-
strates for MAO B. Tryptamine, tyramine, and dopamine are 
metabolized by both forms of the enzyme. Based upon the 
redox-status of the cells and the relative affinities of the 
substrate for the two subsequent enzymes, dopaldehyde is 
either further oxidized to 3 ,4-dihydroxyphenylacetic acid 
(DOPAC) by the enzyme aldehyde dehydrogenase or is reduced 
by the enzyme aldehyde reductase to form 
3,4-dihydroxyphenethanol (DOPET). Typically though, DOPAC is 
the major product of DA oxidation. The catechol moiety of 
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Figure 1: Catecholamine Synthesis 
...... 
...... 
CAs and DOPAC can be a-methylated by the enzyme catechol-0-
methyltransferase (COMT) (Figure 2). 
1. a-methylation of the catecholamines. 
Enzymatic mono-0-methylation of the CAs DOPAC or DOPA 
is performed by the enzyme catechol-0-methyl-transferase 
(COMT) (25) . S-Adenosylmethionine (SAM) is the methyl 
donor. Magnesium is required for the reaction. Predomi-
nantly, the hydroxyl group meta- to the alkyl- side chain of 
the substrate is a-methylated. 
a-Methylation of DOPAC is stereospecific at the 
3-position of the ring and yields 
3-Methoxy-4-hydroxyphenylacetic acid (Homovanillic Acid; 
HVA). a-methylation of DA is also stereoselective at the 
3-position of the ring and produces 
3-Methoxy-4-hydroxyphenethylamine (3-M-DA). This 0-methy-
lated product can be oxidized by MAO and this product, 
3-Methoxy-4-hydroxy-phenyl acetaldehyde is a substrate for 
both aldehyde dehydrogenase and aldehyde reductase. Oxida-
tion by aldehyde oxidase predominates yielding HVA. In the 
corpus striatum of the adult rat the nanomole/gram quanti-
ties of DA, DOPAC, and HVA are 56.9, 11.6, and 3.8 respec-
tively. 
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Figure 2: Dopamine Metabolism 
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2. Norepinephrine synthesis and metabolism. 
As seen earlier, the synthesis of NE requires all of the 
enzymes necessary for DA synthesis. Similiarly, the metabo-
lism of NE shares many of the enzymes which oxidize and 
a-methylate DA. Oxidation of NE by MAO 
3,4-dihydroxymandelic aldehyde. Reduction 
yields 
of 
3, 4 -dihydroxymande 1 ic aldehyde by aldehyde reductase pro-
duces 3,4-dihydroxyphenylglycol; whereas oxidation by aldeh-
yde oxidase 
turn can 
produces 3 ,4-dihydroxymandelic acid which in 
be a-methylated by COMT giving 
3-methoxy-4-hydroxy-mandelic acid. Direct a-methylation of 
NE produces normetanephrine which is a substrate for MAO. 
Oxidation of normetanephrine produces 
3-methoxy-4-hydroxymandelic aldehyde which can be oxidized 
by aldehyde oxidase to give 3-methoxy-4-hydroxymandelic acid 
or it can be reduced by aldehyde reductase to 
3-methoxy-4-hydroxyphenylglycol. These pathways of NE metab-
olism are summarized in Figure 3. 
3. Serotonin synthesis and oxidation. 
The synthesis of the neurotransmitter 5-HT begins with the 
amino acid tryptophan. Tryptophan is hydroxylated by the 
enzyme tryptophan hydroxylase giving 5-hydroxytryptophan 
(5-HTP). 5-HTP is decarboxylated to 5-HT by the enzyme 
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Figure 3: Norepinephrine Metabolism 
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aromatic amino acid decarboxylase. 5-HT is oxidized by MAO 
yielding 5-hydroxyindole acetaldehyde which is further oxi-
dized to 5-hydroxyindole acetic acid (5-HIAA). Reduction of 
5-hydroxyindole acetaldehyde would yeild 
5-Hydroxytryptophol. 5-HIAA is the predominant end product 
of 5-HT metabolism.(Figure 4). 
4. a-methylation of hydroxyindoles. 
The hydroxyindoleamine 5-HT can be a-methylated by the 
magnesium dependent enzyme indole-0-methyl-transferase. SAM 
is the me thy 1 donor. Most of the brain indole-0-methyl-
transferase is located in the pineal gland. 
D. Review of the relevant literature. 
The condensation products mentioned are neuroamine 
derived. Both THIQs and THBCs are taken up into synapto-
somes and stored and thus can be looked upon as "false neu-
rotransmitters". Cohen has studied the in vivo uptake and 
release of THIQs by adrenergic nerves (26). For this reason 
investigators have researched the interactions of these con-
densation products with the enzymes of synthesis and metabo-
lism of the parent neuroamines. 
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Figure 4: Serotonin Metabolism 
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Coscia's research group has examine in detail the bio-
chemical effects of two condensation products: 
desoxynorlaudanosolinecarboxylic acid (DNLCA-the condensa-
tion product of DA and phenylpyruvic acid) and norlaudanoso-
linecarboxylic acid (NLCA-the condensation product of DA and 
3, 4-dihydroxyphenylpyruvic acid) . DNLCA was found to be a 
potent inhibitor of catecholamine metabolism in adrenal 
medulla explants whereas NLCA was not (27). They have found 
DNLCA to be a good inhibitor of tyrosine hydroxylase (28) 
and phenylethanolamine N-methyltransferase (29) whereas NLCA 
is not. Collins and Weiner (30) have shown that various 
catecholic THIQs are potent in vivo inhibitors of tyrosine 
hydroxylase. 3-CSAL was found to be as potent as NE at 
feed-back inhibiting the activity of tyrosine hydroxylase 
(the rate limiting enzyme of dopamine synthesis). Neither 
SAL nor 3-CSAL have any effect in vitro upon liver dopa 
decarboxylase activity (DDC) (30). Catecholic THIQs are 
good substrates for COMT and therefore are competitive 
inhibitors of this enzyme (31). THP can be biotransformed 
by the inclusion of a methyl-bridge to form tetrahydroproto-
berberines by rat liver enzymes. The tetrahydroprotoberbe-
rines are also substrates for COMT (32). THIQs are in vitro 
and in vivo inhibitors of MAO (31,33,34). The norlaudanoso-
line carboxylic acids (condensation products of DA and phe-
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nylpyruvic acid or phenylacetaldehyde) are known inhibitors 
of adrenal dopamine-beta-hydroxylase(35). 
3-CSAL possesses some interesting pharmacological 
properties. Ethanol narcosis has been shown to be potenti-
ated by the DA and L-dopa derived THIQ 3-CSAL (36). 3-CSAL 
has been shown to produce ethanol discrimination in rats 
(37) and has been shown to be as potent as Demerol in pro-
ducing analgesia in the rat (38). 
SAL and 7-M-SAL, as mentioned previously, have been 
detected in mammals. The exact source of this brain SAL is 
not known. A dietary source is not favored because i.p. SAL 
(20 mg/kg i.p. in rats) does not penetrate the blood brain 
barrier (39). 
The possibility of 3-CSAL being taken up into the cen-
tral nervous system and subsequently decarboxylated to SAL 
is one of the questions addressed in this dissertation. Car-
boxylated THIQs have been shown to enter the brain from the 
periphery (4) and it is speculated that the uptake is via 
the neutral amino acid transport system. 
Decarboxylation of 3-CSAL could occur via either an 
oxidative or non-oxidative pathway (See Figure 5). Oxidative 
decarboxylation of 3-CSAL would yield 
1-methyl-6,7-dihydroxy-dihydroisoquinoline (1-methyl-
6,7-dihydroxy-DHIQ). Non-oxidative decarboxylation of 3-CSAL 
would yield SAL. 
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Figure 5: Oxidative versus Non-Oxidative 
Decarboxylation of 3-CSAL. 
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A number of amino acid analogues have been shown to be 
taken up by brain tissue and are non-oxidatively decarboxy-
lated, yielding the corresponding neuroamine analogues (See 
Figure 6). For example, the L-Dopa analogue, alpha-methyl-
dopa (alpha-M-dopa) has been found in brain tissue when 
given peripherally. Acute administration of alpha-M-dopa 
lead to a brain accumulation of alpha-methyldopamine and 
alpha-methylnorepinephrine (40,41,42). Brunner et al (43) 
gave alpha-M-dopa chronically to rats. Again an accumula-
tion of alpha-methyldopamine and alpha-methylnorepinephrine 
was seen. Alpha-methyl-meta-tyrosine (AMMT) given peripher-
ally at a dose of 100 mg/kg intra-peritoneally (i.p.) is 
taken up into the brain where it is decarboxylated and 
beta-hydroxylated to form metaraminol. Maximal striatal 
brain levels of AMMT were seen at 1 hour after the dose was 
given (43). 
In contrast to the above examples, alpha-methyl-para-
tyrosine (AMPT) is not decarboxylated in vivo. Following 
the administration of 80 mg/kg of AMPT to guinea pigs only 
AMPT was found in the heart and brain tissues of these ani-
mals. The tissues were analyzed for alpha-methyl-tyramine 
and alpha-methyl-norsynephrine content 1,2,4,6 and 8 hours 
after the AMPT dose was given. Of the decarboxylated prod-
' 
ucts 0.2 to 0.3 ug/g could have been detected but were not. 
Figure 6: Examples of Amino Acid Analogues. 
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All of the above mentioned examples are compounds hav-
ing primary amines. 3-CSAL is a cyclized secondary amine. 
Pipecolic acid, like 3-CSAL is an imino acid, i.e., it has a 
carboxylic acid moiety attached to a ring which contains a 
secondary amine. In mouse brain, pipecolic acid is decarbox-
ylated to give piperidine (44,45). It is possible that car-
boxylated-THIQs might be substrates for this enzyme as well 
as for aromatic amino acid decarboxylase. 
The possible metabolic routes of 3-CSAL by brain tis-
sue are depicted in Figure 7. It is possible that 3-CSAL 
would be a-methylated at either the 6- or 7- position prior 
to decarboxylation. 3-CSAL itself was shown to be a poor 
inhibitor of DDC and therefore a poor substrate (30). How-
ever 6-M-3-CSAL and 7-M-3-CSAL might well be suitable sub-
strates for DDC producing 6-M-SAL and 7-M-SAL respectively. 
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Figure 7: Some Possible Metabolic Routes for 3-CSAL 
POSSIBLE METABOLIC PATHWAYS l'OB. 3-CSAL 
OOH CH3 
H HI) 
H H -H 
6-M-Sal DDC 
6-:M-3-CSAL 
6 COMT (6-position) 1:l COMT (6-position) 
OOH 
H 
.<J 
H 
DDC 
3-CSAL 
Q COMT (7-position) c emiT (7-position) 
COOH H 
H H l>cH 
3 
DDC 
7-M-Sal 7-M-3-CSAL 
CH 3 
6-M-Sal 
7-M-Sal 
H 
H 
w 
0 
.··~ 
In order to document the actual metabolism of 3-CSAL 
by rats in vivo it was necessary to synthesize de novo all 
the possible metabolites of 3-CSAL seen in Figure 7. Sec-
ondly, the weak cation-exchange resin Bio-Rex 70 (46,47) was 
utilized to isolate 3-CSAL and its possible metabolites as 
well as the neurotransmitters and their metabolites from 
tissue samples. Although the strong cation-exchange resin 
Dowex 50, X-4 has been used by a number of researchers to 
isolate the neurotransmitters and their metabolites (48, 
49,50,51,52,53,54), typically these eluents were directly 
used in a fluorometric assay. Since the compounds bind 
tightly to Dowex (especially the THIQs), either large vol-
umes of acid or high molar concentrations of the acids were 
necessary for elution. 
For gas chromatography and HPLC, it is necessary to 
concentrate the samples. Upon lyophilization of these 
eluents, substantial oxidation of the samples is seen. 
Therefore Bio-Rex 70 is the preferred preparative column 
since small volumes of dilute acid is sufficient for isola-
tion of the amine fraction with good recovery upon lyophili-
zation. 
Appropriate methods of liquid chromatography with 
electrochemical detection were also developed to provide 
resolution and quantitation of all of the compounds of 
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interest within a reasonable time-frame. Chromatographic 
methods in the literature describe separation of the cate-
cholamines by HPLC with cation-exchange (55 ,56 ,57 ,58) or 
HPLC by reverse-phase chromatography with ion-pairing 
(59, 60,61, 62,63, 64). These methods were not utilized for 
the measurement of the biogenic amines and their respective 
acid metabolites in the tissues samples for this disserta-
tion for two reasons: 1) NE and 3-CSAL consistently co-chro-
matographed using the buffers described in the literature 
and 2) 5-HT' s retention time was so great as to severely 
decrease both peak height and sample throughput. 
E. Tissue samples analyzed and experimental strat-
egy. 
Three brain regions were chosen to be analyzed for the 
metabolism of and effects of 3-CSAL: the hypothalamus which 
is rich in NE, 5-HT, and contains DA innervation; the corpus 
striatum which is nearly devoid of NE terminals but has the 
highest DA content of any brain region and has modest 5-HT 
innervation from the raphe nucleus; and the hippocampus 
which has moderate levels of NE and 5-HT but practically no 
DA terminals (65,66). 
The levels of the THIQs in these individual tissues 
will be related to the type of innervation of the individual 
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tissues, and to the levels of the neurotransmitters NE, DA, 
s-HT and their respective acid metabolites. If changes in 
neurotransmitter content were produced by 3-CSAL, they could 
be due to release of neurotransmitters from storage sites 
(displacement) or due to an inhibition of the respective 
neurotransmitter's synthesis or clearance. Experiments in 
which rats are pretreated with an inhibitor of dopa decar-
boxylase would reveal if changes in the neurotransmitter 
levels was due to increased synthesis of 5-HT, i.e. precur-
sor amino acids would accumulate to a greater extent in the 
3-CSAL treated animals versus the appropriate controls. Two 
well characterized inhibitors of DDC are R04-4602 which in 
low doses (50 mg/kg) only inhibits DDC peripherally (however 
BOO mg/kg provides total DDC inhibition) (67,68,69,70) and 
NSD-1015 which provides total (peripheral and central) 
inhibition of DDC when given in low doses (71,72). A car-
boxylated THIQ dose of 50 mg/kg for one hour prior to sacri-
fice was chosen based on the results reported by the inves-
tigators who gave rats i.p. doses of the amino acid 
analogues described earlier. Typically, maximal brain lev-
els of the injected drug were seen at the one hour time 
point. 
Although 3-CSAL is catecholamine derived and it is 
most likely that its neurochemical effects would be upon the 
33 
catecholamines, its effects upon 5 -HT and 5 -HIAA levels in 
the various tissues were determined, predicated upon the 
fact that AMMT, which is also catecholamine derived has been 
shown to lower brain 5-HT (73). 
It was decided to compare aspects of the metabolism 
and neurochemical effects of 3-CSAL to two other carboxylat-
ed-THIQs, 1-CSAL and 1-carboxy-THP, on regional neuro-
transmitters (Figure 8). These THIQs are representative of 
two other alkaloid types, the first being the condensation 
product of DA and pyruvic acid. This compound could be 
formed in diseases in which pyruvic acid accumulates, such 
as subacute necrotizing encephalitis (Leigh's Disease)(74). 
The second is formed in the disease state of Phenylketonuria 
(PKU). 
F. HPLC with electrochemical detection. 
High performance liquid chromatography with electro-
chemical detection (HPLC/EC) is the preferred technique for 
measuring the compounds which have been discussed thus far. 
HPLC/EC was first described by Kissinger et al in 1973 (75). 
The electrochemical detector maintains a voltage applied 
across a 1 microliter volume flow cell through which 
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Figure 8: Carboxylated THIQs Studied. 
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the column eluant passes. For oxidative HPLC/EC, a positive 
voltage is applied across the flow cell and a standing elec-
tron current is maintained. This is known as the background 
current. When an oxidizable compound passes into the detec-
tor cell, the compound gains or absorbs electrons (oxida-
tion), which results in a corresponding drop in the current 
reaching the cathode of the detector. A potentiometer meas-
ures the drop in the current across the cell and compares it 
to a reference voltage set up by a silver/silver chloride 
reference cell. The potentiometer then converts this drop in 
current to a voltage output which in turn drives the chart 
recorder or integrator. 
The detector response for individual compounds relies 
heavily upon several parameters: the intrinsic ease of oxi-
dation of the individual compounds; the voltage applied to 
the cell; the amount of time the compound spends in contact 
with the detector; and the ability of the eluting buffer to 
conduct current and transfer charge. 
The catecholamines, 5 -HT, plus their precursors and 
acid metabolites are among the compounds with the best 
response to electrochemical detection. Similiarly, the con-
densation products derived from these compounds are easily 
detected by HPLC/EC. The magnitude of the voltage applied 
across the detector cell influences the detector response. 
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For each compound there is a specific voltage which gives 
maximum detector response. The HPLC/EC is an inefficient 
detector using a flow rate of 1 ml/min, in that approxi-
mately only 10% of the sample is irreversibly oxidized and 
yet the signal to noise ratio for the detector is very large 
thereby permitting great sensitivity. Much of the lack of 
efficiency is due to the geometry of the detector (lack of a 
large surface area), but equally important is the amount of 
time that the compound is in the detector. If the oxidation 
is a slow process, then increased time spent in the detector 
would permit increased amount of sample oxidized and there-
fore detected. Also, of great consideration is the intrinsic 
electrical conductivity of the eluting buffer. Electrons 
must reach the compound in order to be captured. The 
citrate/phosphate buffers introduced by Kissinger are very 
electrochemically active in the sense that they conduct cur-
rent without generating an appreciable background noise 
(intrinsic resistivity) at the voltages used for optimal 
measurement of the compounds of interest. It is interesting 
to note that a 0.1 M sodium phosphate monobasic buffer pro-
vides a good medium for electrochemical detection whereas a 
0.1 M ammonium phosphate monobasic buffer, pH 5. 0 yields 
poor sensitivity for the compounds of interest as the back-
ground noise by far exceeds the signal reaching the detector 
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when this buffer is used. Therefore it is critical that the 
buffer selected for any chromatography with electrochemical 
detection needs to both accomplish resolution of the com-
pounds chromatographed as well as provide suitable conduc-
tivity for efficient electrochemical detection. 
CHAPTER II 
MATERIALS AND METHODS 
A. Materials. 
Dopamine HCl salt (Sigma) 
Dopamine HBr salt (Aldrich) 
Norepinephrine HCl salt (Sigma) 
Epinephrine HCl salt (Sigma) 
3,4-dihydroxybenzylamine HBr salt (Aldrich) 
Normetanephrine HCl salt (Sigma) 
Metanephrine HCl salt (Sigma) 
Vanilmandelic Acid (Sigma) 
Homovanillic Acid (Sigma) 
3,4-Dihydroxyphenylacetic acid (DOPAC) (Sigma) 
Serotonin Creatinine Sulfate Complex (5-HT) (Sigma) 
5-Hydroxyindole acetic acid (5-HIAA) (Sigma) 
3-D-methyl dopamine (Sigma) 
Salsolinol HCl (de novo) 
6-0-methyl-Salsolinol (de novo ) 
7-0-methyl-Salsolinol (de novo) 
4-0-methyl-dopamine (Calbiochem) 
3-CSAL (de novo) 
L-Dopa (Sigma) 
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Acetaldehyde AR (Fischer) 
4-0-methyl-Dopa (gift: John Daly, NIH) 
3-D-methyl-Dopa (Sigma) 
Pyruvic acid (Sigma) 
Sodium phosphate monobasic monohydrate (Baker) 
Sodium phosphate dibasic heptahydrate (Baker) 
Sodium phosphate dibasic anhydrous (Baker) 
EDTA (Fisher) 
Ammonium phosphate monobasic (Baker) 
Ammonium phosphate dibasic (Fisher) 
1-Heptane sulfonic acid (Kodak) 
Methanol (Kodak) 
Ethyl acetate (Fisher) 
Acetone (Baker) 
Ammonium hydroxide concentrate (Scientific Products) 
Hydrochloric acid AR (Scientific Products) 
Perchloric acid, 60% reagent (Baker) 
Nitric Acid concentrated (Scientific Products) 
Acetic Acid, glacial (Baker) 
n-Butanol (Baker) 
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B. Equipment 
Aminco-Bowman Spectrophotofluorometer with 
Ratio Photometer 
Serval RC2 ultracentrifuge 
FTS Flexi-Dry Lyophilizer 
LC-2A Potentiometer 
TL-5A Amperometric Detector 
LC-19 Silver-Silver Chloride reference electrode 
Bio Rad ODS-10 micron 250mm x 4mm analytical column 
Model SR-204 Heath Single Pen Chart Recorder 
TI-55 Calculator 
Partisil-SCX 10 micron Strong Cation Exchange 
250 x 4 mm analytical column 
Bio-Rex 70 Weak Cation Exchange Resin 
Isolab Minico1umns 
Columns made from Pasteur pipets 
plugged with glass wool 
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C. Methods 
1. The Separation of the Neurotransmitter 
Metabolites Using Bio-Rex 70. 
a. Properties of the Resin. 
Bio-Rex 70 is a polyacrylic resin whose active moiety 
is a carboxylic acid functional group. The carboxylic acid 
functional group will form a salt linkage with primary 
amines only within a narrow pH range of 5.5-6.0. At this pH 
the acid moiety of the resin is unprotonated and therefore 
can form a salt linkage with a cationic species(76). 
The weak cation-exchange characteristic of this resin 
permits the separation of thre~ classes of functional groups 
of the molecules relative to the neurotransmitters: acid/ 
neutral metabolites; the precursor amino acids; and the 
amines. The acid metabolites of the neurotransmitters do not 
bind to the resin at all at pH 5. 5 to 6. 0, and they are 
removed in the void volume and water wash. There is a cou-
lombic repulsion between the acid metabolites and the bind-
ing sites of the resin. The amphoteric molecules such as 
the amino acids bind to the res in, but only weakly. The 
amine moiety of the amino acid forms the salt linkage, but 
the presence of the acid moiety lessens the strength of that 
bond; they are eluted with 0.02 M sodium phosphate buffer, 
pH 6.5. The neuroamines themselves bind best to the resin 
(46) and they are eluted with acid. 
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b. Preparation of the Resin. 
Bio-Rex 70, 200-400 mesh, sodium form was purchased 
from Bio-Rad Laboratories (Richmond, CA). Resin was added to 
a one-liter beaker, enough to occupy the 200 ml mark. The 
resin was then suspended in distilled water. The larger 
resin beads settled to the bottom of the beaker. The finer 
particles, still in suspension, were decanted off with the 
water. This process was repeated until the supernatant is 
clear, i.e. free of fine particles. The sizing of the resin 
ensures that the flow rates of the columns made from the 
resin will be more uniform and faster. 
The resin was then stirred in 3 N ammonium hydroxide 
and allowed to settle. The resin was then washed with dis-
tilled water until the supernatant was neutral. Then the 
resin was stirred in 3 N hydrochloric acid (HCl). Again, it 
was washed with distilled water until the supernatant was 
neutral. Afterwards, 3 N sodium hydroxide was used to gen-
erate the sodium form of the resin. The resin was washed 
then with distilled water until the pH of the supernatant 
was less than 9.0. 
Subsequently, the resin was washed with 0.1 M sodium 
phosphate buffer, pH 6.5, containing 0.1% EDTA. The washing 
was continued until the pH of the supernatant was 6.5. The 
pH of the supernatant was checked the next day to ensure 
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that it remained at 6.5. If it had increased, then the resin 
was washed with fresh buffer. This would be repeated daily 
until the pH of the supernatant remained at 6. 5. This 
exhaustive washing gave better blanks for the fluorescent 
and chromatographic assays. Interferring substances, which 
otherwise would elute with the samples, were removed. 
c. Column Preparation-The Fluorescent Studies. 
Pasteur pipets were used to form mini-columns. Glass 
wool plugs were placed into the bottoms of the pipets and 
enough resin was added to form a 3 em bed. Out of the popu-
lation of pipet-columns thus formed, the ones with flow 
rates of plus or minus one standard deviation of the mean 
were chosen to be used in the experiments. Since the resin 
was stored in 0.1 M phosphate buffer, pH 6. 5, the columns 
were rinsed with 25 ml distilled water prior to use. 
d. Column Preparation-The HPLC Studies. 
Isolab Quik-Sep Columns were used in some of the HPLC 
studies. They were filled with 500 ul of resin. The resin 
filled columns were rinsed with 25 ml distilled water prior 
to using. 
2. Reagents. 
Alkaline ascorbate: 100 mg L-ascorbic acid (Sigma) was 
dissolved in 1.0 ml of quartz-distilled water and 50 ml of 
10 N sodium hydroxide was added. 
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Alkaline sulfite: 1. 25 g sodium sulfate (Baker) was 
dissolved in 5 ml of quartz-distilled water, and 45 ml of 5 
N sodium hydroxide was added. 
Sodium periodate: 0.5% (w/v) sodium periodate (Baker) 
in quartz-distilled water. 
Perchloric acid: 0.4 N (Baker) 
Potassium carbonate:1 N (Baker) 
Potassium ferricyanide: 0.25% (w/v) (Baker) 
3. Buffers. 
0.1 M phosphate, 0.1~~DTA, pH 6.5: 8.28 g sodium phos-
phate monobasic, monohydrate; 5.68 g Sodium phosphate diba-
sic, anhydrous; 10 ml 10% EDTA per liter of quartz distilled 
water. 
0. 02 M phosphate, 0. 2% EDTA, pH 6. 5: 1. 66 g sodium 
phosphate monobasic, monohydrate, 1.14 g sodium phosphate 
dibasic, anhydrous, 20 ml 10% EDTA per liter quartz-dis-
tilled water. 
0. 5 M phosphate, pH 7. 0 (Norepinephrine determina-
tion): 70.98 g sodium phosphate dibasic, anhydrous per liter 
of quartz-distilled water; 68.04 g potassium phosphate mono-
basic, anhydrous per liter of quartz-distilled water. 61.0 
ml sodium phosphate solution was mixed with 39.0 ml of the 
potassium phosphate solution. 
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0.5 M phosphate, pH 7.0 (dopamine determination): A 1 
M solution of potassium phosphate monobasic, anhydrous was 
adjusted to pH 7. 0 with 1 N sodium hydroxide and diluted 
with quartz-distilled water to a concentration of 0.5 M. 
Citrate 0.5 M, pH 4.0: A 1 M citric acid solution was 
adjusted to pH 4. 0 with sodium hydroxide and diluted with 
quartz-distilled water to a concentration of 0.5 M. 
4. Tissue Sample Preparation. 
Animals were sacrificed by a blow on the head and 
decapitation. Brain regions were dissected out as per Iver-
son and Glowinski (77,78), immediately put into weigh boats 
and placed upon blocks of dry-ice. Brain region masses were 
determined using a 5-point Mettler Balance. 
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5. Extraction of the Biogenic Amines, THIQs and Their 
Metabolites from Tissues. 
The samples were extracted either with perchloric acid 
or with ice-cold ethanol. 
Acid extraction: The samples were placed into dispo-
sable test tubes (16 x 100 mm; SP-T1285-6) which contained 
500 ul ice-cold 0. 4 N perchloric acid (O .1% EDTA). Each 
sample was homogenized at maximal speed with a Tissue-Tek 
Homogenizer for 30 seconds. The homogenate was transferred 
to a Serval centrifuge tube. The homogenizer probe and dispo 
test tube were rinsed three times with the perchloric acid 
solution, and the rinses were added to the Serval centrifuge 
tube. The sample tubes were kept on ice throughout the pro-
cedure. The tubes were then transferred to the Serval RC-2 
refrigerated centrifuge and spun for 15 minutes at 18,000 
rpm (4 C). The supernatant was pipetted into 20 ml capacity 
scintillation vials. One of the control samples was split. 
To one half, 100 ng of each of the compounds of interest was 
added. To the other half, distilled water was added. This 
constituted a control for recovery after homogenization. 
The pH of the perchloric acid supernatants were 
adjusted to 5.5-6.0. Initially, this was done coarsely to a 
pH of approximately 4.0, using 2.0 N potassium hydroxide and 
then carefully to pH 5.5-6.0 with 0.2 N potassium hydroxide. 
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Since this was largely an ionic equilibrium, care had to be 
taken not to expose the sample to harsh alkaline conditions 
which could oxidize the compounds investigated. Perchlorate 
ions in excess of those necessary to precipitate the prote-
ins were removed from solution by the potassium ions. The 
two species readily formed the sparingly soluble potassium 
perchlorate salt. It is very important to remove as much of 
the potassium perchlorate from solution as possibe. At 0 
degrees centigrade the solubility of potasium perchlorate is 
0. 7 5 g/ 100 ml; whereas at 25 degrees centigrade 1. 6 g of 
the salt can be dissolved in 100 ml. Failure to remove the 
potasium perchlorate in solution at 25 degrees or at 4 
degrees will result in displacement of members of the amino 
acid fraction into the void volume. Precipitation of this 
salt was enhanced by placing the scintillation vials of pH 
adjusted solutions on a block of dry-ice. As soon as the 
solutions froze completely, they were removed from the dry-
ice and allowed to thaw. The clear solution was pipetted 
away from the precipitate and applied to the pasteur-pipette 
or Isolab columns. 
The effluent, plus a 1.0 ml distilled water wash, was 
collected and labelled the primary eluent. This fraction was 
frozen and lyophylized prior to analysis. The precursor 
amino acids were eluted using 1. 5 ml of 0. 02 M phosphate 
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buffer followed with 1.0 ml distilled water. This fraction 
was labelled the amino acid fraction and frozen at -20 
degrees centrigrade until the fraction was analyzed. The 
amines were e 1 uted with 1. 5 ml of 0. 5 N acetic acid. This 
fraction was labelled the amines and frozen at -20 degrees 
centrigrade until analyzed (Figure 9). Column blanks were 
derived from a column which had no tissue applied to it, but 
was otherwise processed as described above. Thus three 
blanks were generated: a primary eluent fraction blank, an 
amino acid fraction blank, and an amine fraction blank. 
Ethanol extraction: The tissue samples were homogen-
ized in 75% ice-cold ethanol (.5 ml/g tissue). After homogen-
ization and centrifugation as described above, the superna-
tants were diluted 1: 1 with distilled water. When 
separation of the component fractions was necessary, the 
diluted ethanol extract was applied to Bio-Rex 70 columns. 
When chromatography with resolution of all of the compounds 
of interest was possible, the diluted ethanol solution was 
first lyophilized and then reconstituted with 0.1 N HCl and 
directly injected into the high performance liquid chromato-
graph. 
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Figure 9: Bio-Rex 70 Preparative Column Chromatography 
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6. Fluorometric analyses. 
The fluorometric analyses for the amines were adapted 
from those employed by Holman et al (47). 
a. Serotonin. 
A 500 ul aliquot of the amine fraction was placed into 
a disposable test tube. To this 150 ul of 12 N HCl was 
added. The mixture was vortexed and the fluorescence was 
then read at an activation wavelength of 278 nm and an emis-
sian wavelength of 545 nm. External standards, reagent 
blanks and column amine fraction blanks were run each time 
with the samples. Stock solutions were made up in 3 N HCL 
and serially diluted with 3 N HCl to form the standards and 
the standard curve. 
b. Norepinephrine: formation of the 
trihydroxy-indole chromophore. 
To 200 ul of the 0.5 N Acetic acid eluent, 200 ul of 
0.5 M sodium phosphate buffer, pH 7.0, was added. The pH was 
adjusted to a pH of 6.5-7.0, with approximately 600 ul of 1 
M potassium carbonate. An addition of 20 ul of a fresh solu-
tion of 0.25% potassium ferric cyanide was placed into the 
tube; one minute later 200 ul of freshly prepared alkaline 
ascorbate was added; at 15-30 second thereafter, 600 ul of 
distilled water was added. The samples had to be measured 
within 3 to 6 minutes after the initiation of oxidation. The 
fluorescence was monitored at an excitation wavelength of 
336 nm and an emission wavelength of 502 nm. A column amine 
fraction blank was run at the same time. 
c. Dopamine assay: generation of the 
dihydroxyindole chromophore. 
To 200 ul of the 0.5 N acetic acid amine fraction, 100 
ul of pH 7.0 sodium phosphate buffer was added. The pH was 
adjusted to 6.5-7.0 with 1 N potassium carbonate. Oxidation 
was initiated with 100 ul of a 0.5% (w/v) solution of sodium 
periodate. One minute later, 300 ul of the alkaline sulfite 
solution was added. Both the periodate and sulfite solutions 
were made up immediately before use. A 100 ul volume of 0. 5 
M sodium phosphate buffer, pH 4.0 was added, followed by 170 
ul of 3 N phosphoric acid. The fluorescence was measured 
within ten minutes at an excitation wavelength of 316 nm and 
an emission wavelength of 370 nm. Stock solutions and 
serial dilutions were made up with 0.5 N acetic acid. A col-
umn amine fraction blank was run at the same time. 
d. 5-hydroxy-indole acetic acid. 
The native fluorescence of 5-HIAA was measured in 3 N 
HCl. The lyophylized primary eluents were reconstituted 
with 500 ul of 3 N HCl. The excitation wavelength was 290 
nm with an emission wavelength of 545 nm. Standard solutions 
were made of 5-HIAA at a concentration of 1 mg/ml in dis-
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tilled water serially diluted with 3 N HCl. A column blank 
primary eluant fraction was run at the same time. 
e. Tryptophan analysis. 
The tryptophan assay was adapted from the Bloxam and 
Warren (79) modification of the Dewey and Denkla method (80) 
utilizing an excitation wavelength of 373 nm and an emission 
wavelength of 452 nm. The assay was linear in sensitivity 
from 8 ng-4 ug. Tryptophan was converted to the fluorescent 
species, norharman. Glass-stoppered test tubes, which were 
scrupulously cleaned weekly with concentrated nitric acid 
overnight, were used in the assay. 
Two ml of 10% trichloroacetic acid (w/v) was placed 
into the glass-stoppered test tube. A 100 ul aliquot from 
the amino acid fraction was added and the tube was vortexed. 
Then 100 ul of 0. 0061 M ferric chloride in 10% trichlora-
cetic acid was added. The test tube was placed into rapidly 
boiling water for one hour. Turbidity developed in some of 
the test tubes. These samples scattered the light of the 
incident fluorescent beam. To overcome this, the samples 
were centrifuged in a clinical centrifuge at 2,000 rpm for 
five minutes. The clarified samples were then read in the 
spectrophotofluorometer. A column amino acid fraction blank 
was run at the same time. Neither 3-CSAL nor SAL interfered 
with any of the fluorescence analyses described. 
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7. HPLC chromatography. 
Quantitation of the compounds of interest was accom-
plished by means of an electrochemical detector (Bioanalyti-
cal Systems) and was based on peak heights. Kissinger et al 
have recently published a comprehensive review of neurochem-
ical applications of HPLC with electrochemical detection 
(81). For this dissertation, two types of HPLC columns were 
utilized in the quantitation of the compounds of interest: a 
reverse-phase column using an ion suppression buffer and a 
strong cation exchange column. 
Reverse-phase /ion suppression chromatography operates 
on the basis of relative hydrophobicity of the compounds of 
interest in the mobile phase used. The ionic character of 
the biogenic amines and their acid metabolites can be 
expressed or suppressed depending upon the pH of the mobile 
phase. The ionic strength of the mobile phase is not the 
predominant factor in this system. The retention times for 
all of the compounds of interest from a 0.1 M Sodium Phos-
phate buffer (pH 5.0), with 1 mM EDTA are given in Table 4. 
The 0-methyl-SALs were not resolved and had relatively long 
retention times in this system (22.8 min.). Furthermore, 
the acid metabolites eluted in the same vicinity. 
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Table 4 
HPLC RETENTION TIMES OF COMPOUNDS USING 
A BioSil ODS 10 Column and 0.1 M Sodium Phosphate 
Monobasic Monohydrate, 1.0 mM EDTA, pH 5.0. 
COMPOUND RETENTION TIME (MIN) 
Norepinephrine 1.9 
DHBA 3.9 
Dopamine 5.2 
DO PAC 6.8 
5-HT 13.6 
5-HIAA 17.6 
HVA 20.1 
Sal 8.4 
6-M-Sal 22.8 
7-M-Sal 22.8 
1-CSAL 4.0 
6-M-1-CSAL 12.8 
7-M-1-CSAL 16.2 
3-CSAL 4.4 
6-M-3-CSAL 14.4 
7-M-3-CSAL 16.0 
The use of a strong cation-exchange HPLC column (Par-
tisil-SCX) provided not only resolution of the 6- and 
7-M-SALs, but also isolated these compounds away from the 
acid metabolites which now elute in the solvent front in 
this system. The ionic strength and pH chosen to chromato-
graph these compounds provided optimal response and elution 
times while preserving resolution of these compounds. 
Since chromatography of the compounds was done utiliz-
ing a variety of parameters, for all cases, representative 
chromatograms show the conditions utilized. It is possible 
that only trace amounts of decarboxylated products might 
have been present in the samples. Therefore, the limits of 
sensitivity were determined for SAL, 7-0-M-SAL, and 
6-0-M-SAL. The detector signal at twice background was 0.2 
nanoamps. A plot of nanoamps versus nanograms was done for 
each of the compounds. The nanogram value at 0.2 nanoamps 
represents the limit of sensitivity for each of these com-
pounds. The limits of detection were 2.0 ng/ml for SAL, 3.56 
ng/ml for 6-0-M -SAL, and 5. 88 ng/ml 7-0-M-SAL by cation 
exchange HPLC with electrochemical detection. When reverse-
phase HPLC with electrochemical detection was employed, the 
limits of detection were 1.02 ng/ml SAL, 1.82 ng/ml 
6-0-M-SAL, and 3.0 ng/ml 7-0-M-SAL. 
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The student's t-test was used in all of the statisti-
cal analyses. A p value of < 0.05 was considered to be sta-
tistically significant. 
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CHAPTER III 
EXPERIMENTAL SECTION 
All of the subjects were male Sprague-Dawley rats pur-
chased from King Animal Laboratories (Madison, Wise.). All 
of the experiments were initiated at 3 pm Central Standard 
Time and the route of administration of the drug in all 
instances was intraperitoneal injection of the drug in a 
sterile saline vehicle. 
A. Fluorescent Studies. 
1. Acute 50 mg/kg 3-CSAL. 
Sprague-Dawley rats (300-400g) received a 50 mg/kg 
dose of 3-CSAL in a sterile saline vehicle. Saline alone was 
given to the control group. One hour later the animals were 
sacrificed. The corpus striatum and the hypothalamus were 
taken from each animal. Dopamine and norepinephrine levels 
were measured by fluorescence after being isolated using 
Bio-Rex 70 columns. 
2. Acute 50 mg/kg 3-CSAL in animals 
pretreated with a peripheral 
decarboxylase inhibitor, 
R04-4602 (Benserazide). 
60 
Sprague-Dawley rats (300-400g) were pretreated with a 
peripheral dopa decarboxylase inhibitor, R04-4602, at a dose 
of 50 mg/kg. One hour later a 50 mg/kg dose of 3-CSAL was 
given to the experimental group. The control group received 
saline alone. Corpus striatum and hypothalamic tissues were 
assayed. Dopamine and norepinephrine were isolated using 
Bio-Rex 70 and measured fluorescently. 
3. Acute 50 mg/kg 3-CSAL in animals 
pretreated with a total 
decarboxylase inhibitor. 
Male Sprague-Dawley rats (300-400g) were pretreated 
with NSD-1015 at a dose of 100 mg/kg which provided total 
dopa decarboxylase inhibition. The NSD-1015 was adminis-
tered in a sterile saline vehicle to both the experimental 
and the control groups. One hour later, the experimental 
group received a 50 mg/kg dose of 3-CSAL dose in a sterile 
saline vehicle. The control group received the sterile 
saline alone. One hour subsequent to this, both groups of 
animals were sacrificed. Corpus striatum and hypothalamic 
tissues were evaluated. Dopamine and norepinephrine were 
measured by the fluorescent technique after being isolated 
using Bio-Rex 70. 
4. Dose-response study with 3-CSAL. 
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Doses of 50,150, or 400 mg/kg were given to groups of 
male Sprague-Dawley rats (210-270g). Control animals 
received saline alone. One hour later the .animals were sac-
rificed. Dopamine, norepinephrine, and serotonin levels were 
measured in corpus striatum and hypothalamic tissue. The 
neurotransmitters were isolated using Bio-Rex 70 and meas-
ured by fluorescence. 
5. Chronic 3-CSAL (50 mg/kg i.p.). 
A 50 mg/kg dose of 3-CSAL was given to male Sprague-
Dawley rats (112-152g) every eight hours for a total of five 
days. At the same times, the control group received sterile 
saline. One hour after the last injection, the animals were 
sacrificed. Corpus striatum and hypothalamic tissue were 
assayed. Dopamine, norepinephrine, serotonin, tryptophan, 
and 5-hydroxyindole acetic acid were measured fluorometri-
cally after being isolated using Bio-Rex 70. 
B. Animal HPLC studies. 
1. 100 MG/KG 3-CSAL for 30 Minutes. 
Rats (295-340g; 90 days old) were given a 100 mg/kg 
dose of 3-CSAL. Two animals were sacrificed at 15 minutes 
after the dose was given, and four were sacrificed at the 30 
minute time point. Blood, caudate, and hypothalamic tissues 
were taken for analysis. The samples were fractionated using 
Bio-Rex 70 , lyophilized and stored at -20 degrees centi-
grade until assayed by HPLC. 
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2. A Single Dose Time Study. 
Male Sprague-Dawley rats (250-350g; 90 days old) were 
given 3-CSAL (50 mg/kg). The control group was injected 
with the sterile saline alone. At time intervals of one 
hour, three hours, eight hours and twenty-four hours rats 
were sacrificed. The tissues were ethanol extracted. 
Extracts were lyophilized, reconstituted in 0.01 N HCl, and 
directly injected into the high performance liquid chromato-
graph. The corpus striatum was analyzed for its content of 
3-CSAL and its a-methylated metabolites. Dopamine, DOPAC, 
HVA, serotonin, and 5-HIAA were also measured in this tis-
sue. THIQ content was also determined in blood, heart and 
liver. 
3. The effect of 3-CSAL on 5-HT synthesis. 
Male Sprague-Dawley rats (214-407g; 2-10 months) were 
pretreated with 800 mg/kg R04-4602 for one hour. The control 
group was then given sterile saline and the experimental 
group received 50 mg/kg 3-CSAL. One hour later the animals 
were sacrificed. Striatal tissues were extracted with ice-
cold ethanol and placed on Bio-Rex 70 columns. The precursor 
amino acid fraction was collected and analyzed for 
5-hydroxytryptophan content. 
4. The relationship of age of the rat 
to 3-CSAL's effect upon serotonin. 
a. Old rats. 
63 
Male Sprague-Dawley rats (392-455g; 10-12 months) were 
given 3-CSAL (50 mg/kg). The control group received sterile 
saline alone. Eight hours later the animals were sacrificed. 
Hypothalamic and striatal tissues were dissected and ethanol 
extracted. Extracts were lypholized, reconstituted in 0.01 N 
HC 1 and directly injected into the high performance liquid 
chromatograph. 
b. Young rats. 
Young rats (94-105g; 35 days old) were given 3-CSAL 
(50 mg/kg i.p.). The control group received the sterile 
saline vehicle alone. Control and experimental animals were 
sacrificed at 4 and 8 hours after the injections. The stria-
tum and hypothalamus were dissected, extracted with ice-cold 
ethanol, and placed upon Bio-Rex 70 to isolate the amine 
fraction. DA and 5-HT content were determined. 
5. R04-4602 and 3-CSAL. 
The peripheral decarboxylase inhibitor, benserazide 
(R04-4602; 50 mg/kg), was given to male Sprague-Dawley rats 
(196-205g; 50 days old) one hour before they were given a 50 
mg/kg dose of 3-CSAL. The animals were sacrificed one hour 
after the 3-CSAL was given. Control rats received a 50 mg/kg 
dose of R04-4602 and were sacrificed two hours later. Stri-
atal, hypothalamic, and hippocampal samples were extracted 
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with 75% ethanol and analyzed by HPLC for dopamine, seroto-
nin, DOPAC, HVA, and 5-HIAA. 
6. NSD-1015 and 3-CSAL. 
Male Sprague-Dawley rats (200-214g; 52 days old) were 
pretreated with NSD-1015 (100 mg/kg). One hour later, 3-CSAL 
(50 mg/kg) was given to the experimental group. The control 
animals received NSD-1015 only. One hour later, they 
received a saline injection. Two hours after the first 
injection, the rats were sacrificed. The corpus striatum, 
hypothalamus, and hippocampus tissues were extracted with 
75% ethanol and analyzed for their dopamine, DOPAC, HVA, 
serotonin, and 5-HIAA content by direct injection onto the 
HPLC. 
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7. The effect of other carboxylated-THIQs. 
Male Sprague-Dawley rats (140-165g; 42 days old) were 
divided into three groups. The first group received 
1-carboxy-THP at a dose of 50 mg/kg. The second group 
received a 50 mg/kg dose of 1-CSAL. The third group received 
the saline vehicle alone. One hour later the animals were 
sacrificed. Corpus striatum, hypothalamus, and hippocampus 
tissues were analyzed. Dopamine, DOPAC, HVA, serotonin, and 
5-HIAA were quantitated. Levels of 1-CSAL and 1-carboxy-THP 
were determined for the respective groups of rats. 
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CHAPTER IV 
RESULTS 
A. Levels of the THIQs in the tissues analyzed. 
1. 3-CSAL levels-acute studies. 
a. 100 MG/KG 3-CSAL for 30 minutes. 
For rats given a 100 mg/kg i.p. dose of 3-CSAL and 
sacrificed at time points of 15 and 30 minutes, the blood 
levels of 3-CSAL and 6-a-M-3-CSAL, and 7-a-M-3-CSAL are 
given in Table 5. The 3-CSAL blood levels were significantly 
higher (p<0.01) at the 30 minute time point when compared to 
the 15 minute time point. The a-methylated 3-CSAL levels 
were not different between the groups at the time points 
sampled. The Bio-Rex 70 amine fraction from the blood sam-
ples were reconstituted with 250 ul of mobile phase and 100 
ul were placed onto a cation-exchange column. No 6- or 7-
a-M-SAL content was apparent from the chromatogram (Figure 
10). Figure 11 shows the same blood sample spiked with 25 
ng 7-M-SAL (60 ng/ml blood). 
3-CSAL and a-methylated 3-CSALs were measured in the 
striatum. 3-CSAL alone was measured in the hypothalamus 
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TIME 
15 MIN 
30 MIN 
Table 5 
BLOOD LEVELS OF CARBOXYLATED THIQs AT TWO TIME POINTS FOLLOWING 
100 MG/KG I.P. DOSE OF 3-CARBOXY-SAL (NG/ML + S.E.M) 
295-340 g rats (approximately 72 days old) 
3-Carboxy-Sal 6-M-3-Carboxy-Sal 7-M-3-Carboxy-Sal 
553.0 + 18.7 914.6 + 532.7 887.3 + 173.0 
* 1,223.5 + 836.0 808.9 + 493.5 1,224.6 + 610.6 
p 0.01 compared to the 15 minute 3-CSAL level 
(n=2) 
(n=4) 
Figure 10 : Representative Chromatogram 
Blood Sample of an Animal Given 100 mg/kg 3-CSAL 
for 30 minutes. 
Sample: Bio-Rex 70 Amine Fraction; 100 ul of a 250 ul sample. 
Column: Partisil-SCX (10 microns) 
Buffer: 12.61 g Citric Acid, 3.45 g Ammonium Phosphate Monobasic, monohydrate and 
88 m1 1 N Ammonium Hydroxide per liter distilled water. 
Conditions: 1 m1 per minute; 5 nA/V. 
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Figure 11: Blood Sample of an Animal Given 100 mg/kg 3-CSAL 
for 30 Minutes; Spiked with Salsoline. 
Sample: 100 ul of a 250 ul sample of The Amine Fraction from Bio-Rex 70. 
Column: Partisil-SCX (10 micron) 250 mm x 4 mm. 
Buffer: 12.61 g Citric Acid; 3.45 g Ammonium Phosphate Monobasic, monohydrate; 
88 m1 Ammonium Hydroxide per liter distilled water. 
Conditions: 1 m1 per minute; 5 nA/V. 
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since the HPLC column lost its ability to resolve 6- and 
7-M-3-CSAL after the blood and caudate samples were run on 
the HPLC. This was most likely due to irreversible adsorp-
tion of tissue components. The brain levels are given in 
Table 6. The striatal tissue contained a mean level of 2.27 
ug/g 3-CSAL whereas the hypothalamic tissue contained 4.64 
ug/g 3-CSAL at the 30 minute time point. The amine fractions 
from the same tissue samples were chromatographed on both 
cation exchange and reverse-phase columns. 
Figure 12 shows the cation-exchange chromatogram of 
one-fifth of the amine fraction of a caudate of an animal 
given 100 mg/kg 3-CSAL for 30 minutes. No O-M-SAL was seen 
in the sample. Figure 13 shows the same brain sample spiked 
with 6-M-SAL and 7-M-SAL. Figure 14 shows the chromatogram 
of one-fifth of the same caudate extract on a reverse-phase 
column. No SAL was seen to be present in the sample. When 
the sample was spiked with 25 ng of SAL (625 ng/g SAL), the 
SAL chromatographed separately from the peaks for dopamine 
and 5-HT. The SAL did not co-migrate with any endogenous 
peaks in these tissues (Figure 15). 
Table 7 shows the levels of 3-CSAL and its two mono-a-
methyl metabolites in three brain regions one hour after 
3-CSAL injection in untreated rats and in rats pretreated 
with peripheral or central decarboxylase inhibitors. It is 
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TISSUE 
CAUDATE 
HYPOTHALAMUS 
n=4 
Table 6 
BRAIN LEVELS OF CARBOXYLATED THIQs AT 30 MINUTES FOLLOWING 
A 100 MG/KG I.P. DOSE OF 3-CSAL 
3-CSAL 
2.27 + 0.3 
4.64 + 0.4 
UG/G + S.E.M. 
.... 
'.' 
6- and 7-M-3-CSAL 
0.39 + 0.23 
not measured 
Figure 12; Absence of 6- or 7-M-Sal in the Striatum of a Rat 
Given 100 mg/kg 3-CSAL. 
Sample: Amine Fraction from Bio-Rex 70; 100 til of a 500 ul fraction. 
Column: Rsil-Cation Exchange Resin (10 micron) 50 mm x 4mm. 
Buffer: 44.14 g Citric Acid, 12.08 g Ammonium Phosphate Monobasic Monohydrate, 
308 m1 1N Ammonium Hydroxide brought to a final volumn of 1 liter with 
distilled water. 
Conditions: flow rate of 1 m1 per minute; 5 nA/V. 
0.1 v 
60 55 50 45 40 35 30 25 20 15 10 5 0 
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Figure 13: Caudate Spiked with IsoSal and Salsoline (25 ng each) 
Sample: Amine Fraction from Bio-Rex 70; 100 ul of a 500 ul fraction. 
Column: Rsil-Cation Exchange (10 micron) 50 mm x 4 mm. 
Buffer: 44.14 g Citric Acid, 12.08 g Ammonium Phosphate Monobasic Monohydrate, 
308 m1 1 N Ammonium Hydroxide brought to a final volume of 1 liter with 
distilled water. 
0.1 v 
TIME (MIN) 
Q) 
t:: 
•r-t 
...-! 
0 
[J) 
...-! 
1\1 Q) 
[J) t:: 
0 ·r-t 
[J),....j 
H 0 
[J) 
r-1 
1\1 
tJ) 
15 10 5 
78 
D 
E 
T 
E 
c 
T 
0 
R 
R 
E 
s 
p 
0 
N 
s 
E 
0 
Figure 14: Caudate Amine Fraction of an Animal Given 100 mg/kg 
3-CSAL for 30 minutes. 
Sample: Amine Fraction from Bio-Rex 70; 100 u1 of a 500 ul fraction. 
Column: 0.1 M Sodium Phosphate Monobasic Nonohydrate, 1.0 mM EDTA, pH 5.0. 
Conditions: Flow rate of 1 m1 per minute; 10 nA/V. 
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Figure 15 : Bio-Rex 70 Amine Fraction from a Caudate of a Rat given 
100 mg/kg 3-CSAL; Spiked with 25 ng Sal. 
Sample: 100 ul of 1000 ul of the Amine Fraction from Bio-Rex 70. 
Column: BioSil- ODS 10 250 mrn x 4 mm. 
Buffer: 0.1 M Sodium Phosphate Monobasic Monohydrate, 1.0 mM EDTA, pH 5.0. 
Conditions: Flow rate of 1 ml per minute; 10 nA/V. 
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Table 7 
REGIONAL BRAIN 3-CARBOXY-SAL AND 0-METHYLATED 3-CARBOXY-SAL 
ISOMERS ONE HOUR AFTER 3-CARBOXY-SAL (50 MG/KG I.P.). 
UG/G + S.E.M. 
BRAIN REGION 3-CSAL 6M3CSAL 7M3CSAL 
CORPUS STRIATUM 
CONTROL 0.75 + 0.23 0.52+0.10 0.69 + 0.17 
R04-4602 0.20 + 0.04 0.19 + 0.06 0.14 + 0.04 
NSD-1015 0.14 + 0.06 0.03 + 0.03 0.25 + o.os 
HYPOTHALAMUS 
CONTROL 0.20 + 0.02 2.07 + 0.34 1.62 + 0.15 
R04-4602 0.29 + 0.05 1.30 + 0.23 1. 36 + 0.11 
NSD-1015 0.23 + 0.03 1.73 + 0.22 1.74+0.11 
HIPPOCAMPUS 
CONTROL 0.18 + 0.02 0.07 + 0.04 0.15 + 0.06 
R04-4602 0.11 + 0.02 0.09 + 0.02 0.09 + 0.02 
NSD-1015 0.11 + 0.04 0.12 + 0.04 0.14 + 0.02 
apparent that there is decreased brain THIQ content when the 
inhibitors R04-4602 and NSD-1015 were given. 
2. Other carboxylated THIQ levels-acute experiments. 
Tissue levels of 1-CSAL and 1-carboxy-THP are given in 
Table 8. The hypothalamic 1-carboxy-THP content was very 
high when compared to the other to carboxylated THIQs admin-
istered. This was possibly due to the relative lipophilic 
nature of this compound when compared to the others. 
3. THIQ contents between 1 and 24 hours after 
a single dose of 3-CSAL (50 mg/kg i.p.). 
Large sample sizes of heart (O. 9 ± 0.1 g) and liver 
(1.5 ± 0.3 g) and blood (1.5 ml) were taken to ensure that 
if decarboxylation products were present, they could be 
quantitated. The large sample sizes, however, interfered 
with 3-CSAL quantitation because they resulted in corre-
sponding large solvent peaks. Therefore despite a good 
detector sensitivity for 3-CSAL, it could not be assayed in 
these tissues. The retention times for 6-methoxy-3-CSAL and 
7-methoxy-3-CSAL were sufficiently removed from the larger 
peaks and were therefore quantitated. 
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Table 8 
BRAIN CARBOXYLATED THIQ LEVELS FOLLOWING A 50 MG/KG DOSE I.P. 
CARBOXYLATED THIQ 
1-CSAL (n=4) 
CORPUS STRIATUM 
HYPOTHALAMUS 
HIPPOCAMPUS 
1-CARBOXY-THP (n=4) 
CORPUS STRIATUM 
HYPOTHALAMUS 
HIPPOCAMPUS 
UG/G + S.E.M. 
o. 32 + 0.09 
0.56 + 0.05 
0.55 + 0.04 
0.96 + 0.29 
6.48 + 1. 75 
3.10 + 1.07 
00 
V1 
a. Rat serum 0-methylated 3-CSALs. 
As seen in Table 9 and Figure 16, the highest 0-methy-
lated 3-CSAL levels were seen at the 1 hour time point. The 
rate of disappearance of the serum 0-methylated-3-CSALs was 
greater between the 1 hour to 3 hours than between the 3 and 
8 hours. Small amounts of 0-methylated 3-CSALs were present 
at the 24 hour time point. 
b. Rat liver 0-methylated metabolites. 
Table 10 and Figure 17, display the time course for 
levels of liver 0-methylated 3-CSALs after the single (50 
mg/kg) dose of 3-CSAL. The THIQs persisted up to the 24 hour 
period of time. No SAL or 7-M-SAL was seen in any of the 
livers analyzed. At the 30 minute time point the liver 
6-methoxy-3-CSAL content was more than twice the 
7-methoxy-3-CSAL content (p<0.001). The one and three hour 
6-methoxy-3-CSAL contents were not significantly greater 
than the 7-methoxy-isomers. The 8 and 24 hour levels of 
liver 6-methoxy-3-CSAL were significantly greater than the 
7-methoxy-3-CSAL levels. Figure 18 shows a chromatogram of 
6- and 7- methoxy-3-CSAL in liver tissue. 
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Table 9 
RAT SERUM 0-METHYLATED 3-CSAL LEVELS AT VARIOUS TIMES 
AFTER 3-CSAL (50 MG/KG I.P.) NG/ML + S.E.M. 
TIME POINT 6-M-3-CSAL 7-M-3-CSAL 
30 MINUTES 993.20 + 264.50 1089.45 + 373.00 
1 HOUR 552.75 + 155.94 662.32 + 210.62 
3 HOURS 162.79 + 102.40 152.35 + 82.37 
8 HOURS 38.45 + 7.18 30.50 + 10.08 
24 HOURS 7.16 + 5. 14 18.35 + 13.84 
n=4 per time point 
Figure 16: Rat serum a-Methylated THIQ Levels 
3-CSAL Dose-Time Study. 
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Table 10 
RAT LIVER 0-METHYLATED 3-CSAL LEVELS AT VARIOUS TIMES 
AFTER 3-CSAL (50 MG/KG I.P.) UG/G + S.E.M. 
TIME POINT 6-M-3-CSAL 7-M-3-CSAL 
30 MINUTES 2.21 + 0.43 1.03+0.37 
1 HOUR 1.44 + 0.64 1. 08 + 0. 76 
3 HOURS 0.99 + 0.04 0.79 + 0.38 
8 HOURS 0.59 + 0.68 o. 10 + 0.12 
24 HOURS 0.19+0.13 0.04 + 0.03 
n=4 per time point 
Figure 17: Rat Liver THIQ Levels 
3-CSAL Dose-Time Study. 
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Figure 18: Chromatogram of a liver amino acid fraction from an animal 
given 100 mg/kg 3-CSAL for 30 minutes. 
Column: Biosil ODS-10 250mm x 4mm. 
Buffer: 0.1 M Sodium phosphate monobasic, monohydrate pH 5.0.; 1.0 mM disodium EDTA. 
Detector setting: 5 nA/V. 
Flow rate: 1 ml/minute. 
Sample: 100 ul of a 500 ul 0.02 M Sodium phosphate eluant from Bio-Rex 70. 
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There was no evidence of SAL or 6- or 7-methoxy-SAL in 
the rat livers despite the fact that the liver is rich in 
decarboxylases. 
c. Rat heart tissue a-methylated 3-CSALs. 
Table 11 and Figure 19 show the levels of a-methylated 
3-CSALs in heart tissue following a single dose of 3-CSAL. 
The levels of the THIQs in the heart were lower than that 
found in the liver. Neither SAL nor 7-M-SAL was found to be 
present in the heart tissue. The 30 min, 3, 8, and 24 hour 
levels of 6- and 7-M-3-CSALs were not statistically differ-
ent. However at 1 hour there was 73% more 6-M-3-CSAL than 
7-M-3-CSAL (p<0.01). 
d. Striatal levels of 3-CSAL and its two 
a-methylated metabolites after 
3-CSAL (50 mg/ kg i.p.). 
The presence of striatal 3-CSALs was documented in 
Table 12 and Figure 20. The levels were highest at the 1 
hour time point. Based upon the levels at the three hour and 
eight hour time points, the half-life of 3-CSAL was approxi-
mately 120 minutes. Also, there was no evidence of reduc-
tive decarboxylation products in this tissue. 
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Table 11 
RAT HEART LEVELS OF 0-METHYL-3-CSAL ISOMERS AT VARIOUS TIMES 
FOLLOWING 3-CSAL (50 MG/KG I.P.) NG/G + S.E.M. 
TIME POINT 6-M-3-CSAL 7-M-3-CSAL 
30 MINUTES 32.63 + 15.99 27.95 + 12.76 
1 HOUR 49.07 + 18.60 28.44 + 7.35 
3 HOURS 9.67 + 0.26 10.01 + 0.90 
8 HOURS 13.01 + 0. 74 11.50 + 0.65 
24 HOURS 0.00 + 0.00 0.00 + 0.00 
n=4 per time point 
Figure'I9: Rat Heart 0-Methylated THIQ Levels 
3-CSAL Dose-Time Study. 
50.0 
45.0 
40.0 
ng /g 35.0 
+ s • e. m .3 0 • 0 
25.0 
20.0 
15.0 
10.0 
5.0 
1 2 3 4 5 6 
e = 6-Methoxy-3~csAI:. 
• = 7-Methoxy-3-CSAL 
7 8 23 24 
Time (hours) 1.0 00 
TIME POINT 
30 MINUTES 
1 HOUR 
3 HOURS 
8 HOURS 
24 HOURS 
Table 12 
STRIATAL 3-CSAL AND 0-METHYL ISOMERS AT VARIOUS TIMES 
FOLLOWING 3-CSAL (50 MG/KG I.P.) UG/G + S.E.M. 
3-CSAL 
0.69 + 0.21 
0.76 + 0.08 
0.33 + 0.18 
0.00 + 0.00 
0.00 + 0.00 
n=4 per time point 
: .. 
'.' 
6-M-3-CSAL 
1. 13 + o. 36 
1.15 + 0.09 
0.38 + 0.22 
0.00 + 0.00 
0.00 + 0.00 
7-M-3-CSAL 
0.96 + 0.31 
0.81 + 0.08 
0.00 + 0.00 
0.00 + 0.00 
0.00 + 0.00 
Figure 20: Striatal THIQ levels After i.p. 3-CSAL. 
Striatal TIQ Levels After i.p. 3cSAL (50 mg/kg) 
1.25 
© = 3 CSAL 
1.00 "'k = 7-M-3 CSAL 
* 6--M-3 CSAL 
0.75 
LXJIG + s.E.M. 
0.50 
0.25 
1 2 3 Zf 5 6 7 8 
TIME (1-Klt.JRS) 
..... 
0 
..... 
B. The effects of carboxylated THIQs 
on 5-HT and 5-HIAA. 
1. 3-CSAL acute experiments-fluorescent studies. 
a. The effect of 3-CSAL on striatal 
5-HT levels. 
The three i.p. doses investigated were 50, 150, and 
400 mg/kg. As seen in Table 13, striatal serotonin was sig-
nificantly increased for all three doses as compared to the 
control values (+70%; +71%; +90%). Hypothalamic serotonin 
levels were somewhat depressed but the changes were not sig-
nificant at the p<0.05 level. 
b. One-hour pretreatment with the peripheral 
dopa-decarboxylase inhibitor, 
Benserazide (R04-4602). 
When 3-CSAL was given to rats pretreated with 
R04-4602, striatal serotonin was elevated 336% when compared 
to the control levels but 5-HIAA levels were not different 
from the controls. There was no significant difference 
between experimental and control hypothalamic serotonin or 
5-HIAA. The hippocampus showed no difference in serotonin 
or 5-HIAA content levels. See Table 14. 
102 
Table 13 
THE EFFECT OF ACUTE 3-CSAL (50 MG/KG I.P.) ON 
SEROTONIN LEVELS IN RAT STRIATUM AND HYPOTHALAMUS UG/G + S.E.M. 
3-CSAL DOSE 
CONTROL 
50 MG/KG 
150 MG/KG 
400 MG/KG 
STRIATUM 
0.52 + 0.08 
0.89 + 0.16 * 
0.90 + 0.14 * 
0.99 + 0.11 * 
* denotes p < 0. 01 compared to controls. 
Rats 210-270g; 60 days old. 
Measured by Fluorescence. 
n=6 per group 
HYPOTHALAMUS 
1.53 + 0.15 
1.05 + 0.07 
1. 29 + 0.14 
1.41 + 0.19 
...... 
0 
w 
Table 14 
THE EFFECT OF 3-CSAL AND R04-4602 ON REGIONAL BRAIN SEROTONIN AND 5-HIAA 
TISSUE 
CORPUS STRIATUM 
EXPERIMENTAL 
CONTROL 
HYPOTHALAMUS 
EXPERIMENTAL 
CONTROL 
HIPPOCAMPUS 
EXPERIMENTAL 
CONTROL 
UG/G ± S.E.M. 
5-HT 
4.38 + 0.95 * 
1.30 + 0.43 
o. 39 + 0.08 
0.45 + 0.22 
0.34 + 0.01 
0. 38 + 0.01 
5-HIAA 
0.91 + 0.06 
0.88 + 0.11 
0.99 + 0.21 
0. 78 + 0.10 
0.55 + 0.03 
0.53 + 0.03 
* denotes p< 0.01 compared to controls. 
Rats 300-400g; 100 days old. n=4 per group 
Measured by Fluorescence. 
c. One-hour pretreatment with a total 
(central and peripheral) 
dopa decarboxylase inhibitor: NSD-1015. 
Rats pretreated with sufficient NSD-1015 to totally 
inhibit decarboxylation had significantly elevated striatal 
serotonin levels one hour after 3-CSAL when compared to rats 
which were given the inhibitor followed by saline. Striatal 
5-HIAA was significantly depleted when compared to the con-
trol group. 
Hypothalamic serotonin was significantly elevated but 
5-HIAA was not significantly changed when compared to con-
trols For the hippocampus, there was no significant differ-
ence between the serotonin or 5-HIAA for the experimental 
and the control groups (Table 15). 
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Table 15 
THE EFFECT OF 3-CSAL AND NSD-1015 ON REGIONAL 
BRAIN LEVELS OF 5-HT AND 5-HIAA (UG/G + S.E.M.). 
TISSUE 5-HT 5-HIAA 
CORPUS STRIATUM 
EXPERIMENTAL 5.96 + 0.59 ** 0.54 + 0.05 * 
CONTROL 2.29 + 0.21 0.83 + 0.07 
HYPOTHALAMUS 
. EXPERIMENTAL 0.58 + 0.05 * 1.04 + 0.11 
CONTROL 0.41 + 0.04 1.06 + 0.06 
HIPPOCAMPUS 
EXPERIMENTAL 0.39 + 0.02 0.29 + 0.02 
CONTROL 0.43 + 0.06 0.31 + 0.07 
** denotes p <0.01 compared to controls. 
* denotes p <0.05 compared to controls. 
Rats 300-400g; 100 days old. n=4 per group 
Measured by Fluorescence. 
d. The effect of chronic 3-CSAL (5 days) 
on regional brain 5-HT and 5-HIAA levels. 
Following the chronic administration of 3-CSAL, stria-
tal serotonin was significantly depleted to 48% of control. 
The serotonin precursor amino acid, tryptophan was signifi-
cantly elevated by 21% over the control value. 5-HIAA was 
not significantly different between groups. 
In the hypothalamic tissue, serotonin was signifi-
cantly depleted to 82% of the control but there was no sig-
nificant difference in tryptophan content between groups The 
hypothalamic 5-HIAA levels were significantly reduced in the 
experimental group by 24%. See Table 16. 
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TIME POINT 
CONTROL 
30 MINUTES 
1 HOUR 
3 HOURS 
8 HOURS 
24 HOURS 
Table 16 
RAT STRIATAL 5-HT AND 5-HIAA AT VARIOUS TIMES 
AFTER 3-CSAL (50 MG/KG I.P.) UG/G + S.E.M. 
5-HT 5-HIAA 
0.44 + 0.04 0.52 + 0.04 
o. 66 + 0.11 * 0.54 + 0.07 
1.01 + 0.30 * 0.76 + 0.07 * 
1. 32 + 0. 51 * 0.43 + 0.06 
2.08 + 0.60 * 0. 72 + 0.09 * 
0.53 + 0.03 * 0.97 + 0.08 ** 
**denotes pc:::O.Ol compared to controls. 
* denotes p < 0. 05 compared to controls. 
n=4 per time point 
..-
0 
00 
2. HPLC determinations. 
a. The time course effect of a single 
dose 50 mg/kg i.p. of 3-CSAL 
on 5-HT and 5-HIAA. 
The effects of a single 50 mg/kg dose of 3-CSAL was followed 
at the time points of 30 min., 1, 3, 8, and 24 hours. Stria-
tal serotonin was significantly elevated up to 8 hours afer 
3-CSAL was given. At 24 hours, serotonin approached control 
values but it was still significantly higher (20% over con-
trol). 
Striatal 5-HIAA was elevated slightly at 30 min. The 
change however was not statistically significant. At the one 
hour time point there was a significant increase in the 
striatal 5-HIAA. The three hour time point showed a non-
significant decrease in the 5-HIAA levels when compared to 
controls. At 24 hours there was again a significant 
increase in the 5-HIAA levels of the experimental group when 
compared to the controls. See Table 17 and Figure 21. 
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Table 17 
THE EFFECT OF CHRONIC 3-CSAL ON TRYPTOPHAN, SEROTONIN, AND 
5-HIAA IN RAT STRIATUM AND HYPOTHALAMUS UG/G + S.E.M. 
COMPOUND STRIATUM HYPOTHALAMUS 
TRYPTOPHAN 
CONTROL 3.27 + 0.08 5.06 + 0.79 
EXPERIMENTAL 3.96 + 0.17 3.88 + 0.36 
SEROTONIN 
CONTROL 0.33 + 0.01 * 0.37 + 0.01 
EXPERIMENTAL ().16 + 0.02 0.30 + 0.01 
5-HIAA 
CONTROL 0.40 + 0.05 0.77 + 0.04 
EXPERIMENTAL 0.45 + 0.06 0.59 + 0.01 
* denotes p <0.01 compared to controls. 
Rats 112-152g; 40 days old. n= 12 per group 
Measured by Fluorescence. 
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Figure 21: Striatal Serotonergic Changes 
3-CSAL Dose-Time Study. 
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b. The effect of 3-CSAL on 5-HT synthesis. 
If 3-CSAL increased the turnover of 5-HT, then a total 
inhibition of aromatic amino acid decarboxylase by R04-4602 
would lead to an increased accumulation of 5-HTP. Table 18 
demonstrates that 3-CSAL does not increase the synthesis of 
5-HT in decarboxylase inhibited rats. 
c. The age-dependent increase of 
striatal 5-HT by 3-CSAL. 
As can be seen in Tables 19 and 20, 3-CSAL did not 
have a significant effect upon striatal or hypothalamic 5-HT 
content 8 hours after it was given to the older rats. In 
fact the only significant difference between the groups was 
that the HVA content was significantly different between 
groups. When the younger rats were given 3-CSAL, striatal 
5-HT levels were significantly elevated at 4 hours after the 
dose was given. Striatal 5-HT was further elevated at the 8 
hour time point (p<O.Ol) (Table 21). Striatal DA levels 
were not affected at either of the time points investigated. 
The hypothalamus showed no significant difference in either 
DA or 5-HT content. 
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Table 18 
STRIATAL 5-HYDROXYTRYPTOPHAN LEVELS FOLLOWING TOTAL AROMATIC AMINO ACID 
DECARBOXYLATION INHIBITION BY 800 MG/KG R04-4602 FOLLOWED BY 3-CSAL 
GROUP 5-HYDROXYTRYPTOPHAN (UG/G ± S.E.M.). 
CONTROL 18.00 + 4.12 n=5 
EXPERIMENTAL 22.71 + 3.42 n=7 
Rats 214-407g; 6-10 months of age. 
Measured by HPLC. 
.~ 
' : 
Table 19 
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS UPON THE 
CORPUS STRIATUM OF 10 MO OLD RATS UG/G . + S .E.M. 
COMPOUND CONTROL GROUP EXPERIMENTAL GROUP 
DOPAMINE 6.47 + 1.52 6.67 + 2.07 
DOPAC 3.41 + 0.82 1.82 + 0. 60 
5-HT 0.44 + 0.13 0.34 + 0.08 
5-HIAA 0.31 + 0.22 0.43+0.16 
HVA 1.24 + 0.15 0.57 + 0.28 * 
n=4 per group 
*denotes pc:::0.01 as compared to controls. 
Rats 392-455g; 10-12 months of age. 
Measured by HPLC. 
Table 20 
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS 
COMPOUND 
DOPAMINE 
DOPAC 
5-HT 
5-HIAA 
HVA 
UPON THE HYPOTHALAMUS OF OLDER RATS 
UG/G + S.E.M. 
CONTROL GROUP 
0.28 + 0.08 
0.18 + 0.04 
1.69 + 0.39 
0.63 + 0.14 
0.19 + 0.03 
n=4 per group 
Rats 392-455g; 10-12 months of age. 
Measured by HPLC. 
EXPERIMENTAL GROUP 
0.38 + 0.14 
0.17 + 0.04 
1. 66 + 0.28 
0.69 + 0.15 
0.36 + 0.05 
Table 21 
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS 
UPON THE CORPUS STRIATUM OF YOUNGER RATS UG/G + S.E.M. 
GROUP DOPAMINE 5-HT 
4 Hour Saline 5.54 + 0.65 0.63 + 0.14 n=4 
4 Hour 3-CSAL 4.99 + 0.43 1.00 + 0.09 * n=5 
8 Hour Saline 4.90 + 0.54 0.78 + 0.13 n=4 
8 Hour 3-CSAL 4.97 + 0.38 1.21 + 0.05 * n•5 
Combined Controls 5.22 + 0.39 0.69 + 0.08 
* denotes p< 0.01 as compared to the time matched controls. 
Rats 94-105g; 35 days of age. 
Measured by HPLC. 
The 
d. The effect of other carboxylated THIQs 
on 5-HT and 5-HIAA. 
1. One hour after 1-CSAL (50 mg/kg i.p.). 
dopamine-pyruvic acid condensation product, 
1-CSAL, had a significant effect upon the striatal seroton-
ergic system, resulting in significantly elevated 5-HT lev-
els. 5-HIAA also was significantly elevated in this tissue. 
1-CSAL had no effect on the hypothalamic serotonin 
content. However a 5-fold elevation of 5-HIAA was seen in 
this tissue. 
Neither hippocampal 5-HT nor 5-HIAA was affected by 
the dose of 1-CSAL (Table 22). 
2. One hour after 1-carboxy-THP 
(50 mg/kg i.p.). 
1-carboxy-THP, the condensation product of dopamine 
and 3,4-dihydroxyphenylpyruvic acid, significantly increased 
both 5-HT and 5-HIAA content in the corpus striatum. 
Both hypothalamic and hippocampal 5-HT and 5-HIAA con-
tents were unaffected by this acute dose of 1-carboxy-THP. 
See Table 23. 
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Table 22 
REGIONAL BRAIN 5-HT AND 5-HIAA LEVELS ONE HOUR FOLLOWING 
ACUTE 1-CSAL TREATMENT (50 MG/KG I.P.) UG/G + S.E.M. 
TISSUE 
CORPUS STRIATUM 
EXPERIMENTAL 
CONTROL 
HYPOTHALAMUS 
EXPERIMENTAL 
CONTROL 
HIPPOCAMPUS 
EXPERIMENTAL 
CONTROL 
5-HT 
1.26 + 0.16 * 
0.51 + 0.02 
1.06 + 0.10 
0.96 + 0.04 
0.18 + 0.02 
0.23 + 0.02 
5-HIAA 
1.32 + 0.15 * 
o. 72 + 0.07 
1.56 + 0.10 ** 
0.30 + 0.02 
0.20 + 0.02 
0.23 + 0.02 
** denotes ~ 0.01; * denotes p <0.05 as compared to controls 
n==4 per group 
Rats 140-165g; 42 days of age. 
Measured by HPLC. 
Table 23 
REGIONAL BRAIN 5-HT AND 5-HIAA LEVELS ONE HOUR FOLLOWING 
ACUTE 1-CARBOXY-THP TREATMENT (50 MG/KG I.P.) UG/G + S.E.M. 
TISSUE 5-HT 5-HIAA 
CORPUS STRIATUM 
'EXPERIMENTAL 1.42 + 0.18 * 1.69 + 0.14 * 
CONTROL 0.51 + 0.02 0. 72 + 0.07 
HYPOTHALAMUS 
EXPERIMENTAL 0.90+0.10 0.24 + 0.04 
CONTROL 0.96 + 0.04 0.30 ± 0.02 
HIPPOCAMPUS 
EXPERIMENTAL 0.27 + 0.05 0.26 + 0.05 
CONTROL 0.23 ± 0.02 0.23 + 0.02 
* denotes p c::O.OS as compared to controls. 
Rats 140-165g; 42 days of age. n•4 per group 
Measured by HPLC. -N 0 
C. The effects of carboxylated THIQs on the levels of 
catecholamines and their acid metabolites. 
1. Acute fluorometric determinations. 
a. Striatal and hypothalamic catechol-
amine content one hour after 3-CSAL. 
One hour after the 50 mg/kg i.p. 3-CSAL dose, there 
was a non-significant decrease of striatal and hypothalamic 
dopamine. Hypothalamic norepinephrine levels were not sta-
tistically different between groups (see Table 24). 
b. Striatal and hypothalamic content 
one hour after 3-CSAL (50 mg/kg i.p.) 
in Benserazide (R04-4602) treated rats. 
When preceded by a peripheral decarboxylase inhibitor, 
the 50 mg/kg dose of 3-CSAL lowered striatal dopamine to 
52.3% of the level of the control group (Table 25). Hypoth-
alamic dopamine was also significantly reduced, but not to 
the same degree. Hypothalamic norepinephrine content was 
not altered. 
c. Striatal and hypothalamic content 
one hour after 3-CSAL (50 mg/kg i.p.) 
in NSD-1015 pretreated rats. 
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Table 24 
REGIONAL CATECHOLAMINE LEVELS ON HOUR FOLLOWING ACUTE 
3-CSAL TREATMENT (50 MG/KG I.P.) UG/G + S.E.M. 
TISSUE LEVELS 
CORPUS STRIATUM 
CONTROL DA 7.88 + 0.76 
EXPERIMENTAL DA 6.73 + 1.45 
HYPOTHALAMUS 
·CONTROL DA 2.11 + 0.25 
EXPERIMENTAL DA 1.97 + 0.98 
CONTROL NE 2.38 + 0.21 
EXPERIMENTAL NE 2.52.+ 0.59 
Rats 300-400g; 100 days old. n=5 per group 
Measured by Fluorescence. 
....... 
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Table 25 
REGIONAL CATECHOLAMINE LEVELS ONE HOUR FOLLOWING R04-4602 
AND ACUTE 3-CSAL TREATMENT (50 MG/KG I.P.) UG/G ± S.E.M. 
TISSUE LEVELS 
CORPUS STRIATUM 
EXPERIMENTAL DA 4.31 + 0.44 ** 
CONTROL DA 8.24 + 0.50 
HYPOTHALAMUS 
EXPERIMENTAL DA 2.12 + 0.12 * 
CONTROL DA 2.86 + 0.09 
EXPERIMENTAL NE 1. 98 + 0.19 
CONTROL NE 2.62 + 0.13 
** denotes P< 0.01; * denotes p<O.OS as compared to controls 
Rats 300-400g; 100 days of age. n=6 per group 
Measured by Fluorescence. 
In the presence of a total dopa decarboxylase inhib-
itor, 3-CSAL significantly reduced striatal dopamine levels 
when compared to rats given the inhibitor alone. Hypo- tha-
lamic dopamine levels were not significantly affected. 
Hypothalamic norepinephrine content was not significantly 
affected (Table 26). 
d. Striatal dopamine levels one hour 
following increasing doses of 3-CSAL 
(50, 150, or 400 mg/kg i.p.). 
The effect of the 3-CSAL at the doses of 50, 150, or 
400 mg/kg was investigated. As seen in Table 27, there was 
no significant effect upon striatal dopamine levels by any 
of the doses given. 
2. HPLC determinations. 
a. The effect of chronic 3-CSAL 
(50 mg/kg i.p., three times 
daily for 5 days) on catecholamines. 
One hour following the final dose of 3-CSAL, the stri-
atal and hypothalamic dopamine of the experimental group 
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Table 26 
REGIONAL CATECHOLAMINE LEVELS FOLLOWING TREATMENT WITH A TOTAL 
DECARBOXYLASE INHIBITOR FOLLOWED BY ACUTE 3-CSAL (50 MG/KG I.P.) 
FOR ONE HOUR. UG/G + S.E.M. 
TISSUE LEVELS 
CORPUS STRIATUM 
CONTROL DA 7.32 + 0.47 ** 
EXPERIMENTAL DA 4. 74 + o. 71 
HYPOTHALAMUS 
CONTROL DA 1.97 + 0.04 
EXPERIMENTAL DA 2.05 + 0.29 
CONTROL NE 2.29 + 0.24 
EXPERIMENTAL NE 1.89 + 0.21 
** denotes P< 0.01 as compared to controls. 
Rats 300-400g; 100 days of age. n=6 per group 
Measured by Fluorescence. 
Table 27 
THE EFFECT OF ACUTE 3-CSAL (50 MG/KG I.P.) ON DOPAMINE 
LEVELS IN THE CORPUS STRIATUM UG/G + S.E.M. 
DOSE OF 3-CSAL LEVELS 
CONTROL 7.32 + 0.47 
50 MG/KG 7.29 + 0.88 
150 MG/KG 6. 35 + 0. 53 
400 MG/KG 6.65 + 0.56 
Rats 210-270g; 60 days of age. 
Measured by Fluorescence. 
n•6 per group 
-~-~-
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were essentially the same as that of the control group. 
Hypothalamic norepinephrine levels were unchanged (See Table 
28). 
b. Acute 3-CSAL studies-catecholamine 
and metabolite studies. 
1. Striatal levels of DA, DOPAC, and HVA 
between 30 minutes and 24 hours after 
3-CSAL (SO mg/kg i.p.). 
The effect of a single SO mg/kg dose of 3-CSAL was 
followed at the time points of 30 min., 1, 3, 8, and 24 
hours. The levels of striatal dopamine, DOPAC, and HVA are 
listed in Table 29. There was no statistical difference in 
striatal dopamine levels at any of the times compared to the 
control group. 
Thirty minutes post dosage, there was no significant 
difference in DOPAC levels as compared to the controls. 
Non-statistical increases in DOPAC levels were seen at one 
and three hours. Eight hours after the dose of 3-CSAL, stri-
atal DOPAC was elevated greater than two-fold as compared to 
the controls The twenty-four hour DOPAC levels were also 
significantly elevated. The DOPAC elevation was greater at 
twenty-four hours than at eight hours. 
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Table 28 
THE EFFECT OF CHRONIC 3-CSAL ON DOPAMINE AND NOREPINEPHRINE 
IN RAT STRIATUM AND HYPOTHALAMUS UG/G + S.E.M. 
DOPAMINE STRIATUM HYPOTHALAMUS 
CONTROL 8.43 + o. 73 2.86 +·0.46 
EXPERIMENTAL 8. 38 + 1.24 2.87 + 0.40 
NOREPINEPHRINE 
CONTROL 2.22 + 0.16 
EXPERIMENTAL 2.24 + 0.31 
The 3-CSAL was given every 8 hours for 5 days. Animals 
were sacrificed 1 hour after the last dose. 
Rats 112-152g; 40 days of age. 
Measured by Fluorescence. n•12 per group 
.... 
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Table 29 
DA, HVA, AND DOPAC LEVELS IN THE CORPUS STRIATUM AT VARIOUS 
TIMES AFTER ACUTE 3-CSAL (50 MG/KG I.P.) UG/G + S.E.M. 
TIME POINT DOPAMINE DO PAC HVA 
CONTROL 7.13 + 0.88 2.13 + 0.09 1.13 + 0.06 
30 MINUTES 7. 87 + 1.24 2.03 + 0.07 0.48 + 0.19 ** 
1 HOUR 7.78 + 0.61 3.08 + 1.02 0.98 + 0.44 
3 HOURS 7.09 + 1. 95 2.82 + 0.83 1.05 + 0.07 
8 HOURS 9.15 + 2.32 4.50 + 0.32 
** 1. 35 + 0.06 * 
24 HOURS 8. 75 + 1.17 5.19 + 0.42 
** 1.69 + 0.51 * 
** denotes p < 0.01; * denotes p <0.05 as compared to controls. 
Rats 250-350g; 90 days of age. 
Measured by HPLC. n=4 per group 
The HVA levels were significantly lowered at the 
thirty minute time point as compared to the controls. At 
one and three hours, the HVA levels of the experimental 
groups were statistically the same as that for the control 
group. At eight hours the HVA levels for the experimental 
group was significantly elevated over that for the control 
group. The HVA levels were further elevated at twenty four-
hours. See Figure 22. 
2. Levels of DA, DOPAC, and HVA in striatum 
and hypothalamus following 3-CSAL 
(50 mg/kg i.p.) in Benserazide (R04-4602) 
pretreated rats. 
Striatal dopamine was significantly depleted in the 
experimental group. Striatal DOPAC levels were also signif-
icantly depleted, but HVA levels remained unchanged. 
While the peripheral dopa decarboxylase inhibitor plus 
3-CSAL had effects upon the dopaminergic system in the cor-
pus striatum, no effects were seen in the hypothalamus: 
there was no significant effect on dopamine levels; HVA lev-
els were non-significantly lowered (Table 30). 
3. Animals given a total decarboxylase 
inhibitor followed by 3-CSAL. 
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Figure 22: Striatal Dopaminergic Changes 
3-CSAL Dose-Time Study. 
p 
E 24o 
R 220 
c 200 
E 180 
N 
T 160 
140 
0 
F 120 
100 
c 80 
0 
N 
60 
T 40 
R 20 
0 
L 
Dopaminergic Changes In Rat Striatum 
After i.p. 3cSAL · 
rl* 
• = DA 
~· • = DOPAC Y= HVA 
J- ~ 
* p <o.os vs control 
1 2 3 4 ~ 6 7 8 23 24 
Time (hours) I-" w N 
Table 30 
THE EFFECT OF 3-CSAL AND R04-4602 ON REGIONAL DOPAMINE, 
DOPAC, AND HVA LEVELS 
TISSUE 
CORPUS STRIATUM 
EXPERIMENTAL 
CONTROL 
HYPOTHALAMUS 
EXPERIMENTAL 
CONTROL 
DOPAMINE 
3.68 + 0.12 ** 
, 
7.04 + 0.33 
1.60 + 0.10 
i 
1.73 + 0.18 
UG/G + S.E.M. 
DO PAC 
0.66 + 0.06 * 
1.09 + 0.11 
0.20 + 0.03 
0.15 + 0.02 
HVA 
0.48 + 0.06 
0.48 + 0.07 
0.18 + 0.05 
0.24 + 0.06 
** denotes p<!0.01; * denotes P< 0.05 as compared to controls. 
Rats 196-205g; 50 days of age. 
· Measured by HPLC. n•4 per group 
Total dopa decarboxylase inhibition followed by 3-CSAL 
resulted in a significant depletion of dopamine levels in 
the corpus striatum. DOPAC levels for the experimental 
group were significantly reduced when compared to controls. 
Also, HVA levels were significantly less for the experimen-
tal group when compared to the controls. 
The experimental treatment produced no significant 
difference in hypothalamic dopamine levels when compared to 
the controls; DOPAC levels were significantly elevated and 
there was a large non-significant increase in HVA levels. 
See Table 31. 
4. The effect of 1-CSAL (50 mg/kg i.p.) 
on catecholamine and acid levels. 
A 50 mg/kg i. p. dose of 1-CSAL had no effect upon 
striatal dopamine or DOPAC levels after one hour. However a 
significant effect (p<0.01) of 1-CSAL upon the striatal 
dopaminergic system is indicated by the increased HVA lev-
els. 
The hypothalamic dopaminergic system was more exten-
sively affected by 1-CSAL. Hypothalamic dopamine and DOPAC 
were significantly elevated when compared to controls. Con-
trary to the striatum, hypothalamic HVA levels were not 
altered by acute 1-CSAL. See Table 32. 
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Table 31 
TISSUE DOPAMINE AND ACID METABOLITES LEVELS FOLLOWING 
TOTAL DECARBOXYLASE INHIBITION AND 3-CSAL (50 MG/KG I.P.). 
TISSUE 
CORPUS STRIATUM 
EXPERIMENTAL 
CONTROL 
HYPOTHALAMUS 
EXPERIMENTAL 
CONTROL 
UG/G + S.E.M. 
DOPAMINE 
5. 90 + 0. 53. * . 
7.62 + 0.43 
1.68 + 0.34 
1. 66 + 0.16 
DOPAC 
0.24 + 0.03 ** 
0.36 + 0.02 
0.22 + 0.02 * 
0.16 + 0.01 
HVA 
0.31 + 0.10 * 
0.53 + 0.04 
2.80 + 0.27 
1.67 + 0.75 
** denotes p< 0.01; * denotes p< 0.05 as compared to controls. 
Rats 200-214g; 52 days of age. n•4 per group 
Measured by HPLC. .... IJ,) 
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Table 32 
TISSUE DOPAMINE AND ACID METABOLITES FOLLOWING 1-CSAL 
UG/G ± S.E.M. 
TISSUE DOPAMINE DOPAC HVA 
CORPUS STRIATUM 
EXPERIMENTAL 7.81 + 1.06 1. 85 + 0.24 0.89 + 0.07 * 
CONTROL 7.65 + 0.74 1.78 + 0.10 0.43 + 0.10 
HYPOTHALAMUS 
EXPERIMENTAL 2.66 + 0.09 * 0.56 + 0.14 ** 0.28 + 0.04 
CONTROL 2.08 + 0.23 0.34 + 0.08 0.30 + 0.02 
** denotes p < 0.01; * denotes p < 0.05 as compared to controls. 
Rats 140-165g; 42 days of age. n•4 per group 
Measured by HPLC. 
5. The effect of 1-carboxy-THP (50 mg/kg i.p.) 
on the catecholamine and acid 
metabolite levels. 
A 50 mg/kg i.p. dose of 1-carboxy-THP had no effect 
upon the striatal dopamine or DOPAC levels after one hour. 
However striatal HVA levels were significantly elevated by 
acute 1-carboxy-THP treatment. Hypothalamic DA, DOPAC, and 
HVA levels for the experimental group was not statistically 
different from controls (Table 33). 
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Table 33 
TISSUE DOPAMINE AND ACID METABOLITES FOLLOWING ACUTE 
1-CARBOXY-THP (50 MG/KG I.P.) UG/G ± S.E.M. 
TISSUE DOPAMINE DO PAC HVA 
CORPUS STRIATUM 
EXPERIMENTAL 8.18 + 0.76 1. 98 + 0.05 0.93 + 0.13 * 
CONTROL 7.65 + 0.75 1. 78 + 0.10 0.43 + 0.01 
HYPOTHALAMUS 
EXPERIMENTAL 2.21 + 0.21 0.48 + 0.10 0.24 + 0.04 
CONTROL 2.08 + 0.23 0.34 + 0.08 o. 30 + 0.02 
* denotes p< 0.05 as compared to controls. 
-w 00 
Rats 140-165g; 42 days of age. n•4 per group 
Measured by HPLC. 
CHAPTER V 
DISCUSSION 
A. Lack of evidence for in vivo decarboxylation 
of 3-CSAL to SAL or a-methyl-SALs. 
Animals given a 100 mg/kg dose of 3-CSAL had rela-
tively greater THIQ levels at 30 minutes than at the 15 min-
ute time point. Non-oxidative decarboxylation of 3-CSAL or 
of its a-methyl metabolites could have produced SAL, 
6-M-SAL, or 7-M-SAL. Despite the fact that large (ug/g) lev-
els of 3-CSAL were present in the blood and brain, neither 
SAL, 7-M-SAL, nor 6-M-SAL was seen. Based on the electro-
chemical responses (and corresponding limits of sensitiv-
ity), SAL had to constitute <0. 05% of the 3-CSAL (10 .17 
nMoles/g) found in the striatum, or <0.02% of the injected 
THIQ (20.77 nMoles/g) present in the hypothalamus if it were 
to be present at analysis. The blood contained 5.48 
nMoles/ml 3-CSAL. Neither SAL nor a-methylated SALs were 
seen in the blood. Based upon the 5. 48 nMole/ml level of 
3-CSAL, <0.09% of the 3-CSAL was decarboxylated peripherally 
in animals given a 100 mg/kg i.p. dose of 3-CSAL for 30 
minutes. SAL was not apparent in heart or liver tissues ana-
lyzed even though these tissues are rich in decarboxylases. 
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Collins and Weiner (30) previously noted that 3-CSAL 
was not an inhibitor of DDC in vitro further indicating that 
3-CSAL is a poor substrate for this enzyme in rats. Rela-
tively high levels of 6-M-3-CSAL and 7-M-3-CSAL were seen in 
the brain tissue but no 6-M-SAL or 7-M-SAL were detected 
there above the limits of sensitivity described above. It 
is probable then that the 0-methylated-3-CSALs are also poor 
substrates for decarboxylases. Simi liar to the 3-CSALs, 
alpha-methyl-para-tyrosine is not decarboxylated in vivo. 
In contrast, 1-dopa analogues such as alpha-MD and AMMT are 
readily decarboxylated non-oxidatively in vivo 
(40,41,42,43). Also 3-CSAL was not decarboxylated by the 
enzyme which decarboxylates pipecolic acid to piperidine 
(44,45). 
THIQs carboxylated at the 1-position can be oxida-
tively decarboxylated in vitro to their corresponding 
3,4-dihydroisoquinolines by anodic oxidation at low electro-
chemical potentials (82), prolonged treatment in neutral 
aqueous media (83), and by the plant enzymes laccase and 
peroxidase (84). Origitano found <57 pMoles of 
1,2-dihydro-SAL but large amounts of 1-CSAL present in the 
brains of rats chronically treated with 1-CSAL (91). Rapid 
a-methylation and conjugation of the carboxylated THIQs 
might be expected to block the oxidative decarboxylation. 
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B. Is it possible that 3-CSAL is metabolized 
beyond a-methylation? 
a-methylation and decarboxylation were the two major 
routes of metabolism of the carboxylated THIQs which were 
addressed in this dissertation. It is possible that other 
routes of metabolism exist for the carboxylated THIQs. Tri-
metoquinol is a catechol THIQ with known bronchodilation 
activity(85). Only 11.5% of trimetaquinol is excreted as 
the free drug; 27.5% is excreted as a-methylated trimetaqui-
nol; and 61% is excreted as the glucuronide conjugate. Sul-
fate conjugation of biogenic amines and their metabolites is 
also an important pathway of metabolism in brain. 
N-oxidation is another metabolic alternative. Various 
drugs such as pentobarbital and ethanol are known to induce 
hepatic microsomal oxidative systems. Dajani and Saheb (16) 
found that varying metabolic conditions could favor oxida-
tion of beta-carbolines both in vitro and in vivo. The 
products were N-oxides. It is possible therefore that an 
alternate pathway of THIQ metabolism could be the formation 
of N-oxides and fully aromatic compounds. Hamilton and Gause 
(86) have suggested the formation of N-oxides from SAL and 
DesmethylSAL after incubation in mild alkaline conditions. 
C. Lack of in vivo stereospecificity for a-methylation 
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of 3-CSAL by COMT. 
Endogenous catecholamines have been shown to be ster-
eospecific substrates for COMT. Catecholic THIQs have been 
shown to be inhibitors of COMT in vitro (87) and in vivo and 
themselves are a-methylated (88,89,90). Studies with puri-
fied rat liver COMT have monitored the stereospecific O-rne-
thylation of DesmethylSAL and its N-methyl analog (89), and 
THP (32). Consistently, the compounds were predominantly 
a-methylated at the 7-position. Bail et al (89) found that 
SAL and NorSAL, given centrally to rats, were predominantly 
a-methylated at the 7-position. Origitano et al (91) found 
that SAL and 1-CSAL (both DA derived catecholic THIQs) were 
stereo-specifically a-methylated at the 7- (para) position. 
This is in contrast to DA which is specifically a-methylated 
meta-to the side chain. 
L-dopa, the parent amine of 3-CSAL is stereospecifi-
cally a-methylated at the hydroxyl group meta- to the side 
chain in vivo (87). 3-CSAL is however non-specifically 
a-methylated. Equal amounts of 6-M- and 7-M-3-CSAL were 
found in the serum of animals given a dose of 3-CSAL. Origi-
tano deduced that a hydrophobic region may be present in the 
active site of COMT which prevents random binding of sub-
strates (91). Charged groups on substrate molecules are 
directed away from the hydrophobic centers giving a stereos-
pecific orientation. The presence of the carboxylic acid 
moiety at the 3-position in 3-CSAL provides an equal oppor-
tunity for a-methylation at either the hydroxyl group meta-
or para- to the side chain. 
D. The levels of 6-M-3-CSAL were consistently 
higher than 7-M-3-CSAL in tissue samples. 
The levels of the two a-methylated isomers of 3-CSAL 
were essentially the same in the serum samples analyzed. 
When a single dose of 3-CSAL was followed over a 24 hour 
period of time, there was no difference in content of the 
two isomers at the 30 minute time point. However, signifi-
cantly more 6-M-3-CSAL was present in the brain than 
7-M-3-CSAL at both the 1 and 3 hour time points (p<0.01). At 
the 30 minute time point the liver 6-M-3-CSAL content was 
more than twice the 7-M-3-CSAL content (p<O. 001). The one 
hour 6-M-3-CSAL content was non-significantly greater than 
the 7-M-3-CSAL content. At the 3 hour time point the 
6-M-3-CSAL levels were non-statistically greater than the 
7-M-isomer. The 8 and 24 hour liver levels of 6-M-isomer 
were significantly greater than the 7-M-isomer. In heart 
tissue, the 30 minute, 3, 8, and 24 hour levels of the two 
isomers were not statistically different. However at 1 hour, 
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there was 73% more 6-M-3-CSAL than 7-M-3-CSAL (p<O.Ol). One 
hour after a 50 mg/kg i. p. dose of 3-CSAL hypothalamic 
6-M-3-CSAL was 24% greater than the 7-M-3-CSAL content. 
There are several possibilities for these results. One 
is that the 6-M-isomer is formed more easily than the 
7-M-isomer. A second explanation could be significantly 
better storage of 6-M-3-CSAL than the 7-isomer in nerve ter-
minals. A related third explanation is that either conjuga-
tion, N-oxidation and/or exodus of the 7-isomer is much 
faster in these tissues. 
E. The effects of the THIQs: neurotransmitter content 
and turnover in the tissues analyzed. 
The presence of the THIQs in the different brain 
regions, and the neurochemical effects seen must be viewed 
in light of the type of innervation that the tissue 
receives, and the relative turnover of the respective bio-
genic amine neurotransmitters. Smith et al. (92) ranked 
seven brain regions with respect to neurotransmitter content 
and turnover. The seven brain regions examined were the cer-
ebral cortex, diencephalon (which contains the hypothala-
mus), hippocampus, mesencephalon, pons-medulla, striatum, 
and telencephalon. A summary of their work is provided in 
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Table 34. With a rank of 1 being highest and 7 being lowest, 
we can use the ranking system of Smith et al. to rate the 
tissues analyzed in this dissertation. 
The striatum has the highest DA content and the fast-
est DA turnover; although the striatum ranked sixth in 5-HT 
content, the turnover of 5-HT was ranked second. The hypo-
thalamus ranked fourth in both DA content and turnover; 
hypothalamic 5-HT ranked second in content, but turnover of 
5-HT was ranked seventh (slowest). The hippocampus was 
ranked seventh in content and sixth in turnover for both DA 
and 5-HT. However, the effect of 3-CSAL does not seem to be 
attributable to increased synthesis since 5-HTP did not 
accumulate above control levels when its decarboxylation was 
inhibited. 
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Table 34 
A SUMMARY OF RANK OF SEVEN BRAIN TISSUES BY BOTH 
NEUROTRANSMITTER CONTENT AND TURNOVER 
SEROTONIN DOPAMINE 
TISSUE CONTENT TURNOVER CONTENT TURNOVER 
CEREBRAL-CORTEX 5 5 3 3 
DIENCEPHALON 2 7 4 4 
HIPPOCAMPUS 7 6 7 6(a) 
MESENCEPHALON 3 1 6 6(a) 
PONS-MEDULLA 1 4 5 5 
STRIATUM 6 2(a) 1 1 
TELENCEPHALON 4 2(a) 2 2 
Rank of !=Highest; Rank of 7=Lowest 
(a)=tie between the turnover rates for these two tissues. 
Adapted from Smith et al. Prog. Neuro-Psychopharm. 2: 359-367 (1978). 
F. Acute 3-CSAL elevates striatal 5-HT 
without consistently lowering 5-HIAA. 
Acute experiments with 3-CSAL have demonstrated a 
rather specific effect upon the serotonin content of the 
corpus striatum. Serotonin and 5-HIAA levels in the hypotha-
lamus and hippocampus were unaffected at the one hour time 
point despite the fact that 3-CSAL and its 0-methylated 
metabolites were present in these tissues. The effects of a 
single 50 mg/kg dose of 3-CSAL was assessed at the time 
points of 30 minutes, 1, 3, 8, and 24 hours. Fig 22 shows 
the percent relative concentrations of 5-HT and 5-HIAA at 
these time points. At the 30 minute time point, 5 -HT was 
significantly elevated whereas 5-HIAA was unaffected. This 
would be consonant with increased synthesis of 5-HT. At the 
one hour time point, both 5-HT and 5-HIAA were significantly 
elevated, but synthesis exceeded catabolism, as one might 
see in the case of increased turnover. At three hours after 
the dose was administered, 5-HT was further elevated but 
5-HIAA was not different from the control levels. By 24 
hours of time, the levels of both 5-HT and 5-HIAA were 
returned to the normal range. 
The eight hour maximal effect upon striatal 5-HT does 
not correlate with the levels of the 3-CSAL, which is nearly 
undetectable at this time. This fact raises the possibility 
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that unanalyzed metabolites of 3-CSAL were present and 
affected the 5-HT system. 
Quipazine is a drug which increases whole brain 5-HT. 
Medon et al (93) found that quipazine was a potent blocker 
of 5-HT uptake. Jacoby et al (94) saw that quipazine 
increased whole brain 5-HT levels while significantly 
decreasing 5-HIAA by 35% one hour post a 10 mg/kg injection. 
Regionally, the striatum was the least sensitive to quipa-
zine effects whereas the greatest activity was seen in the 
hypothalamus. This is the converse of 3-CSAL' s regional 
effects. Fuller et al (95) documented the effects of quipa-
zine on serotonin metabolism in rat brain. Quipazine 
decreased 5-hydroxytryptophan accumulation when the total 
aromatic amino acid decarboxylase inhibitor NSD-1015 was 
given. Thus the increase in 5-HT was not due to MAO inhib-
ition but rather by the fact that quipazine acts as a sero-
tonin receptor agonist. The results of the synthesis experi-
ment suggests that 3-CSAL acts in the same way. 
Ho et al (96) investigated the mechanism of serotonin 
elevation by 6-methoxy-THBC. This compound exerted no effect 
upon mouse brain tryptophan hydroxylase. 6-methoxy-THBC did, 
however, produce a significant facilitation of labeled 5-HTP 
uptake into mouse brain. In another publication, Ho et al 
(97) stated that 6-methoxy-THBC did not affect norepineph-
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rine levels but did alter 5-HT levels. Since NE was 
unchanged, they speculated that the 5-HT increase was not 
due to the inhibition of MAO activity. Subcellular frac-
tionation studies in mouse brain showed a significant 
increase in the particulate fraction of "bound" 5-HT. The 
6-methoxy-THBC slowed the disappearance of intracisternally 
injected labeled 5-HT, but had no effect upon the levels of 
5-HIAA. Increased binding of 5-HT was suggested as a mecha-
nism for the effect of 6-methoxy-THBC' s "protection" of 
brain 5-HT. Shields and Eccleston (98) have offered evi-
dence for the synthesis and storage of 5-HT in two separate 
pools in the brain. In their experiment, animals were given 
labeled tryptophan followed by LSD, which decreases the fir-
ing rate of 5-HT neurons. They found that the conversion of 
labeled tryptophan to labeled 5-HT was changed, but the 
overall rate of 5-HT formation was not changed. 5-HT formed 
from tryptophan was called the functional pool of 5-HT, 
whereas the other 5-HT formed was called the reserve pool of 
5-HT. When DDC was totally inhibited, 3-CSAL still elevated 
5-HT. Thus if increased synthesis was the source of the ele-
vated 5-HT, the 5-HT must be coming from the "reserve pool". 
It is speculated that perhaps 3-CSAL increases the bound 
fraction of 5-HT, protecting the neurotransmitter from 
metabolism. However, further studies would be necessary to 
answer this question. 
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G. The relationship of age to the effect 
of 3-CSAL on 5-HT. 
The weight gain with respect to age for Sprague-Dawley rats 
on normal rations is shown in Figure 23. By 35 days of age 
the rats are fertile. At King Animal Laboratories (Madison, 
Wise.) breeding begins at 42 days of age (6 weeks). The typ-
ical weights for these animals are 125-150g for the females 
and 150-175g for the males. More success in breeding is seen 
in 63 day old rats (9 weeks). Typically, these females weigh 
175-200g and the males weigh 225-250g. 
Proven breeders are animals which have raised two con-
secutive litters to the age of weaning. However if an animal 
fails to continue to produce litters it becomes a retired 
breeder; typically females are retired by King by 6-8 months 
of age; males are retired at 8-10 months of age. By 9 
months of age the estrous cycle in the female becomes pro-
longed and with further aging the animal becomes anestrous. 
Considering the fact that the life expectancy of a rat can 
be up to 36 months, retired breeders have only lived 25% of 
their life expectancy and yet they have clearly aged. The 
CNS of the rat does not achieve developmental maturation 
until 2 months of age (99). The levels of dopamine, dopamine 
sensitive adenyl cyclase, synaptosomal dopamine uptake and 
tyrosine hydroxylase are stable between 2-12 months of age. 
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Figure 23: The relationship of age to gram weight in male Sprague-Dawley rats. 
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After this time dopamine levels, receptors, tyrosine hydrox-
ylase levels, and dopamine sensitive adenyl cyclase levels 
decline. 
Vasko et al. (100) have measured steady state levels 
of brain acetylcholine in young (28 days), adult (90 days), 
and old (24 months) male Holtzman rats. Despite the fact 
that there was no difference in steady state brain control 
levels of acetylcholine, Vasko found marked changes in brain 
acetylcholine in response to d-amphetamine in young and old 
rats, but not in the adults. Timiras (101) found that cho-
line acetyltransferase activity does not change markedly 
from 2-12 months in rat cerebellum and cerebral hemispheres. 
But choline acetyltransferase activity in the spinal cord 
decreased significantly with age. 
Both young and mature male Sprague-Dawley rats showed 
a significant increase in striatal 5-HT 8 hours after 3-CSAL 
was administered. However this effect was not seen in older 
rats. It is possible to speculate that the differences 
between groups could be related either to a loss of neurons 
due to aging, a reduced regional blood flow, an age related 
altering of metabolic pathways, or to altered 5-HT turnover. 
Marquis et al (102) have demonstrated dopamine receptor 
alterations in aging mouse and rat striatum. Cubells and 
Joseph (103) also have shown an age related DA receptor loss 
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in rats. Samorajski (104) has demonstrated decreased stria-
tal DA synthesis in older rats. Synaptosomal DA uptake is 
reduced in hypothalamic and striatal synaptosomes of aged 
mice (105). Striatal adenyl cyclase activity is signifi-
cantly lower in aged mice (106,107) and rabbits (108). Also 
dopamine content of the human striatum is significantly 
decreased in older subjects (109,110). It is not clear 
whether the DA neurons per se or their metabolic abilities 
are required for 3-CSAL's effect upon striatal 5-HT. 
Ohata et al (111) have shown that there is no signifi-
cant difference in striatal or hypothalamic blood flow in 
rats at the ages investigated. Therefore the difference in 
5-HT effect seen is not related to perfusion. It is possi-
ble that relative competency of peripheral drug metabolism 
by the liver could account for the change in effect with 
respect to age. For example, Macklon et al (112) have shown 
that older patients are not able to metabolize diazepam as 
quickly as younger adults. Also, the lean mass or relative 
percent body fat could be different between groups. With 
more body fat, a fat soluble drug may not realize the same 
brain drug levels as a lean animal would. The exact reason 
for the lack of an 8 hour effect of acute 3-CSAL is not 
readily clear, but it is reproducible. 
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H. Chronic 3-CSAL reduces 5-HT in both 
the striatum and the hypothalamus. 
The acute studies consistently demonstrated an 
increase in striatal 5 -HT levels. However, chronic 3-CSAL 
administration significantly depleted striatal 5-HT to 48% 
of the control values. Tryptophan, the precursor amino acid 
for 5-HT, was significantly elevated in the striatal tissue 
of the experimental animals. However, striatal 5-HIAA levels 
were not significantly different between the groups. 
Chronic 3-CSAL also produced a significant depletion 
of 5-HT in the hypothalamus. Hypothalamic tryptophan was not 
significantly different between groups but 5-HIAA was sig-
nificantly depleted. The fact that a hypothalamic effect 
was seen chronically but not at the one hour time point 
could well be related to the fact that 5-HT turnover is very 
slow in the hypothalamus. 
The mechanism of the 5-HT depletion by chronic 3-CSAL 
is unclear as are the effects of other THIQs upon the sero-
tonergic system which have been reported in the literature. 
Livrea (113) saw a paradoxical change in the serotonergic 
system's response to THP when acutely or chronically admin-
istered. When THP was given acutely at a dose of 60 mg/kg, 2 
hours post injection 5-HIAA was significantly elevated. This 
elevation was short lived in that 5-HIAA levels returned to 
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normal at 4 hours post injection and remained so when fur-
ther checked at 6 and 12 hours post injection. Chronic THP 
(8 mg/kg) significantly lowered 5-HIAA levels. Livrea con-
cluded that this was a result of decreased turnover. Another 
explanation however is that this decrease could have 
resulted from a toxic effect upon serotonergic neurons. Sim-
ilar to the neurotoxicity of 3-CSAL is the neurotoxicity of 
halogenated phenethylamines and amphetamines. Chronic doses 
of these drugs cause marked depletion of 5-HT(ll4-121). 
It is unknown whether or not 3-CSAL is taken up into 
serotonin nerve endings. It is known however that the deple-
tion of 5-HT by 1-Dopa is independent of uptake into 5-HT 
neurons by the serotonin pump (122). One approach to answer 
this question is to lesion the 5-HT system of rats with 
5, 7-dihydroxytryptamine followed by 3-CSAL administration. 
The resultant levels and disappearance of 3-CSAL and its 
mono-0-methyl metabolites could be measured in all 7 of the 
brain regions described by Smith et al and compared to con-
trol levels. A low accumulation of 3-CSAL in 
5, 7 -dihydroxytryptamine lesioned animals may indicate the 
necessity of uptake of the THIQs into the serotonergic nerve 
endings for the effects upon the serotonergic system to be 
seen. When followed by experiments which block uptake into 
the serotonergic system by the serotonin pump, it would be 
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possible to define if 3-CSAL uptake into serotonergic neu-
rons is necessary for the increase of 5-HT to be seen. 
I. 3-CSAL after pretreatment with decarboxylase 
inhibitors elevates 5-HT and 5-HIAA is 
unchanged or lowered. 
When a peripheral DDC inhibitor was given prior to 
3-CSAL, striatal 5-HT was elevated 3 fold compared to con-
trols whereas 5-HIAA levels were unchanged. For both the 
hippocampus and hypothalamus neither 5-HT nor 5-HIAA levels 
were altered despite the fact that 3-CSAL and its mono-0-me-
thyl metabolites were present in these tissues. It is not 
yet known if 5-HT content in these brain regions would be 
affected at other time points. It is known however that of 
the tissues analyzed, 5-HT turnover is fastest in the cau-
date. 
Also, animals pretreated with the total decarboxylase 
inhibitor followed by 3-CSAL had significantly elevated 5-HT 
levels and lower 5-HIAA levels in the striatum. Hypothalamic 
5-HT was elevated with this treatment, but 5-HIAA levels 
were decreased. Neither 5-HT nor 5-HIAA levels were altered 
in the hippocampus. In none of the experiments has there 
been a hippocampal 5-HT effect although 3-CSAL levels are 
157 
detected in this tissue. The increases in 5-HT by 3-CSAL 
seen when decarboxylase inhibitors were given could be due 
to MAO inhibition, activity as a serotonin agonist, or 
facilitated 5-HT turnover and uptake. The increases in ser-
otonin seen were similiar to the MAO inhibition by beta-car-
bolines described by Ho et al (97). Meyerson et al (123) 
demonstrated that MAO A, the 5-HT specific oxidase, was more 
sensitive to inhibition by isoquinolines than was MAO B. 
The hypothalamic changes seen with the total decarboxylase 
inhibitor resemble MAO inhibition. However, other experi-
ments indicate that 3-CSAL does not inhibit MAO in vivo (Dr. 
Collins; personal communication). Thus there is a synergis-
tic action of NSD-1015 and 3-CSAL which resembles MAO inhib-
it ion. 
J. Other carboxylated THIQs studied also 
alter brain serotonin content. 
Acute 1-CSAL i.p. significantly elevated both 5-HT and 
5-HIAA in the striatum. In another brain area, the hypotha-
lamus, however, 1-CSAL appeared to increase 5-HT turnover at 
one hour, as suggested by the elevated 5-HIAA levels with 
no change in 5-HT levels. Origitano (91) found similiar 
results in the hypothalamus when 1-CSAL was given intraven-
tricularly. 
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It is of interest to note that the 5-HT and 5-HIAA 
levels were increased in the striatum for both of the geo-
metric isomers of carboxylated-SAL. This could indicate a 
similiar mechanism of action in the striatum. The 3-carboxy 
isomer however achieved significantly higher brain levels 
than did the 1-carboxy isomer. The hypothalamic effect of 
1-CSAL was dissimiliar to the 3-carboxy isomer. In none of 
the experiments with 3-CSAL as the sole drug given was 
5-HIAA elevated in the hypothalamus. 
There was no effect of 1-CSAL upon hippocampal 5-HT or 
5-HIAA levels at the time point examined despite the fact 
that tissue levels of 1-CSAL were seen. In contrast, when 
the 1-CSAL was given intraventricularly, (Origitano (91)), 
an increase in hippocampal 5-HIAA was seen. The differences 
in these results may lie in the dose and route of adminis-
tration. Another explanation for the increased hippocampal 
5-HIAA could be due to displacement of 5-HT stores. Uptake 
and release of THIQs have been described by Cohen et al 
(124), but they did not examine carboxylated THIQs. 
Peripherally administered 1-carboxy-THP significantly 
elevated 5-HT and 5-HIAA in the striatum. The hippocampal 
and hypothalamic 5-HT and 5-HIAA content were unaffected. 
The levels of 1-carboxy-THP were the highest in the hypotha-
lamus and yet there was no serotonergic effect in that tis-
sue at this one hour time point. 
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K. 3-CSAL does not alter DA levels. 
Acute 3-CSAL treatment had no effect upon striatal DA 
or hypothalamic DA or NE content. Increasing the dosage of 
3-CSAL also had no effect upon striatal DA content, further-
more chronic exposure to 3-CSAL (5 days) had no effect upon 
striatal DA or hypothalamic NE or DA. 
When the acid metabolites of DA (HVA and DaPAC) were 
analyzed, it could be seen that DA turnover was probably 
increased by acutely administered 3-CSAL. The data from the 
single-dose/time course experiment revealed that the HVA 
levels were significantly lowered at the 30 minute time 
point. This was probably due to the fact that 3-CSAL was 
competing with DaPAC or DA for the enzyme caMT. At the one 
and three hour time points HVA levels had returned to nor-
mal, suggesting either that 3-CSAL was mostly a-methylated 
by this time or that some compensatory mechanism was in 
effect. At the eight hour time point, the HVA levels were 
significantly elevated over the control levels. Remembering 
that DA levels were not different than those for the con-
trols, one can conclude that DA turnover has been acceler-
ated. HVA levels were further elevated at the 24 hour time 
point, which suggests that dopaminergic activity was still 
elevated despite the fact that neither 3-CSAL nor its a-me-
thylated metabolites were detected in the tissues at the 24 
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hour time point. Again, the possibility that other metabo-
lites of 3-CSAL were active at these time points must be 
considered. 
The striatal DOPAC levels were not significantly dif-
ferent for the controls at the 30 minute time point. Non-
statistical increases in DOPAC levels were seen at the one 
and three hour time points. A statistically significant ele-
vation in DOPAC levels were seen at the 8 and 24 hour time 
points. These results concur with the theory of increased 
dopaminergic activity in the corpus striatum. More precise 
information could be gained using radiolabeled 1-dopa to 
follow the turnover of DA when 3-CSAL is given. 
L. 3-CSAL and DDC inhibitors lower DA levels in rats. 
Striatal DA was significantly depleted in 3-CSAL 
treated animals pretreated with R04-4602 such that periph-
eral DDC was inhibited. In this experiment striatal DOPAC 
levels were significantly decreased when compared to con-
trols. However HVA levels were no different between groups. 
These results suggest that DA turnover was not increased by 
3-CSAL. 
When 3-CSAL was preceded by total decarboxylase inhi-
biton by NSD-1015, DA levels also were significantly 
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depleted. This drug combination produced striatal DOPAC lev-
els which were significantly lower compared to the controls. 
Thus 3-CSAL produced lower DOPAC levels when DDC was 
either peripherally or totally inhibited. The decarboxylase 
inhibitors prevented the replenishment of DA and subse-
quently its acid metabolites. 
No 3-CSAL hypothalamic effect upon the dopaminergic 
system was seen in animals pretreated with peripheral DDC 
inhibitor, but central DDC inhibition in tandem with 3-CSAL 
did produce a hypothalamic dopaminergic effect; there was no 
decrease in dopamine levels, but DOPAC levels were signifi-
cantly elevated for the experimental group. These findings 
suggest an increased DA turnover as a real effect of 3-CSAL. 
However, the possibility of increased turnover requires ver-
ification by an alternate method. 
M. Other carboxylated THIQs and DA levels. 
1-CSAL affected the striatal dopaminergic system, as 
seen by statistically increased HVA levels in the experimen-
tal group. There was, however, no difference in striatal DA 
and DOPAC levels between the experimental and control 
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groups. Thus in the striatum either turnover was increased 
or 1-CSAL competed with HVA for egress from the system. 
Origitano (91) found that 1-CSAL intraventricularly had 
increased striatal HVA and DOPAC but had no effect on DA. 
The lack of agreement between these results must be viewed 
in light of the differences in dose and route of administra-
tion. 
The hypothalamic dopaminergic system was affected by 
1-CSAL in a different way. Hypothalamic dopamine as well as 
DOPAC was significantly elevated when compared to controls. 
HVA levels however were not altered. Thus it appeared that 
peripheral 1-CSAL increased the synthesis and turnover of 
DA. Central 1-CSAL (91) had no effect on DA or HVA and sig-
nificantly decreased hypothalamic DOPAC content. Again, it 
is interesting to note the differences in results from the 
central versus peripheral administration 
In the striatum DA levels were unaffected by acute 
1-carboxy-THP; DOPAC levels also were unchanged; only stria-
tal HVA was elevated, Again, this was either due to an 
increased DA turnover or a decreased egression of HVA. 
Whereas 1-CSAL had an effect upon the hypothalamic dopamin-
ergic system, 1-carboxy-THP had no effect upon any of the 
components of the hypothalamic dopaminergic system assayed. 
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The effects of the carboxylated THIQs on DA systems 
can be compared to the effects of non -carboxylated THIQs. 
When Livrea et al (113) administered THP acutely, levels of 
HVA in rat brain first increased at 2 hours post dose, 
decreased by 4 hours, and returned to normal at 6 to 12 
hours. The acute changes were explained as aDA displacement 
and HVA elevation followed by DA and HVA depletion. This was 
subsequently followed by recovery. When THP was given 
chronically, the Livrea group saw that HVA levels 12 hours 
after the final dose were no different than that for the 
control groups. Awazi and Guldberg ( 125) reported that 
striatal DA levels were unaffected 3 hours after a centrally 
administered 10 ug dose of THP. Paradoxically, THP doses of 
70 to 250 ug resulted in lower DA levels. 
In separate experiments SAL and THP have been given 
intraventricularly to rats in "physiological doses" acutely 
(126). Low doses of SAL (40-200 ng) produced no significant 
change in catecholamine levels in the pons or striatum. 
Awazi and Guldberg (125) found that after a 250 ug 
dose of SAL striatal DA was elevated 5 to 6 hours later, 
and diencephalic NE content was reduced significantly. Halo-
peridol, the DA receptor antagonist blocked the SAL induced 
changes in the DA contents. Thus this THIQ and others may 
well interact with DA receptors. 
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It appears that all of the THIQs investigated affect 
the turnover of DA. It would be of great interest to see in 
future experiments if haloperidol or other DA receptor 
antagonists block the effects of the carboxylated THIQs 
reported in this dissertation. 
N. Central interactions between dopaminergic 
and serotonergic systems. 
Since 3-CSAL has been demonstrated to affect both 
dopamine turnover and 5-HT levels in the corpus striatum, it 
is fitting to speculate that these facts may be related. 
Researchers have demonstrated interactions between the 
dopaminergic and serotonergic systems of the central nervous 
system. For example, 5-HT is involved in the 1-dopa induced 
cortical synchronization in the rabbit (127). Unilateral 
nigrostriatal lesions in rats followed by apomorphine pro-
duces contralateral turning responses and stereo-typic gnaw-
ing (128). The rate of contralateral turning was signifi-
cantly decreased by pretreatment with 5-HTP. The 
effectiveness of apomorphine induced turning was enhanced by 
depletion of 5-HT by p-chlorophenylalanine or by blockade of 
5-HT receptors by methysergide. 
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Serotonin appears to diminish many aspects of behav-
ioral arousal. When 5-HT is depleted by p-chloro-phenyl-
alanine locomotion in response to 1-dopa is increased (129). 
Green (130) has seen an enhancement of amphetamine action 
after interruption of ascending serotonergic pathways by 
electrolytic lesions. The inhibitory function of 5-HT is 
reinforced by the fact that the threshold dosage of amphet-
amine required to elicit stereotypic behavior in the guinea 
pig are decreased by methysergide and increased by 5-HTP. 
Also, 5-HTP reverses abnormal jaw, mouth and other movements 
produced by 1-dopa in monkeys with tegmental lesions (132). 
Amphetamine induced locomotion and stereotypy are signifi-
cantly elevated after p-chlorophenylalanine pretreatment of 
rats (133). The 1-dopa induced emission of seminal fluid has 
been shown to be mediated through 5-HT mechanisms (134). 
0. Interactions between DDC inhibitors and 3-CSAL 
Both peripheral and total decarboxylase inhibition 
followed by 3-CSAL resulted in significantly elevated stria-
tal 5-HT and significantly depleted striatal DA. The common 
factor between NSD-1015 and R04-4602 is that the both 
inhibit peripheral decarboxylation. This leads to elevated 
serum levels of 1-dopa and tryptophan. If peripheral decar-
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boxylase inhibition results in decreased striatal levels of 
tyrosine then a mild inhibitor of tyrosine hydroxylase could 
significantly reduce dopamine levels. 
P. Behavioral effects of 3-CSAL. 
Known behavioral effects of 3-CSAL are analgesia (38) 
and potentiation of ethanol induced narcosis (36). It is a 
distinct possibility that these effects are mediated through 
3-CSAL' s effect upon 5-HT. Fibiger et al. (135) have shown 
that animals pretreated with the tryptophan hydroxylase 
inhibitor p-chloro-phenylalanine were more reactive to elec-
tro-shock. This sensitivity could be reversed by injecting 
the animals with 5-HTP. Fluoxitine, which inhibits the ser-
otonin-amine pump, has been shown to produce analgesia in 
rats receiving electro-shock (136). Fluoxitine also 
reverses the p-chloro-phenylalanine induced hyperalgia. Qui-
pazine, which is a serotonin receptor agonist produces anal-
gesia in rats tested by the hot plate method (137). 
The dorsal raphe nucleus sends 5-HT projections to the 
pontine recticular formation. Jouvet (138,139) has provided 
evidence that the serotonergic system is involved in the 
sleep process. Elevating 5-HT in the pontine recticular for-
mation prolongs deep sleep. The work of this dissertation 
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has shown 5-HT to be elevated in the striatum, one could 
speculate then that the potentiation of ethanol induced nar-
cosis by 3-CSAL could be through elevated pontine recticular 
5-HT. 
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CHAPTER VI 
SUMMARY 
3-CSAL was used as a test alkaloid to see if carboxy-
lated THIQs are decarboxylated in vivo in a rat model. When 
given intraperitoneally, large amounts of 3-CSAL and its 
mono-a-methyl metabolites were taken up into the brain. In 
contrast, SAL itself when given i.p. does not enter the 
brain to any appreciable extent due to the blood brain bar-
rier(39). No appreciable decarboxylation of 3-CSAL or its 
mono-a-methyl metabolites to THIQs was seen in any of the 
tissues analyzed ( <1%). The oxidative decarboxylation of 
3-CSAL to DHIQs was also found to be negligable (<1%). 
In contrast to other THIQs such as SAL, 1-CSAL, and 
THP which are stereospecifically a-methylated, 3-CSAL was 
mono-a-methylated to an equivalent extent on both available 
hydroxyls of the ring. Despite the fact that serum levels 
of the two a-methylated isomers of 3-CSAL were essentially 
the same, tissue levels of the 6-M-isomer were consistently 
higher than the 7-M-isomer. It is speculated that the 
7-M-isomer has a meta- hydroxyl available for conjugation or 
sulfation which would lead to its more rapid clearance. The 
6-M-isomer has the 7-hydroxyl remaining, but this site may 
not be preferred for these reactions. 
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Levels of THIQs were highest when no inhibitor of DDC 
were given. It is possible that 1-dopa and 5-HTP which accu-
mulate with the decarboxylase pretreatment compete with 
3-CSAL and its mono-0-methylated metabolites for uptake into 
the brain. Levels of the THIQs were consistently highest in 
the hypothalamus which has the greatest serotonergic inner-
vation of any of the tissues analyzed. It is suggested that 
carboxylated THIQs may be preferentially taken up into sero-
tonergic neurons. 
Summaries of the effects of 3-CSAL upon the dopaminer-
gic system and serotonergic systems are provided in Tables 
35 and 36 respectively. These two tables state the changes 
in the levels of the particular neurotransmitters and their 
acid metabolite(s) with respect to the various experimental 
conditions examined. Increases are depicted by the upward 
arrow; decreases by the downward arrow; and no significant 
difference by the horizontal arrow. 
Levels of DA were relatively unaffected by carboxylat-
ed-THIQs unless animals were pretreated with decarboxylase 
inhibitors. Turnover of DA appears to be increased by car-
boxylated-THIQs in certain brain regions, but the signifi-
cance of the mild dopaminergic effect is not understood at 
this time. 
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Table 35 171 
A SUMMARY OF CARBOXYLATED-THIQs EFFECTS UPON 
THE STRIATAL DOPAMINERGIC SYSTEM 
CONDITION DA DOPAC HVA 
ACUTE 3-CSAL 
30 Min. .... -+ l 
1 Hr. 
-+ .... .... 
3 Hr. 
-+ .... ..... 
8 Hr. -+ t f 
24 Hr. .... t f 
R04-4602 and ~ l ..... Acute 3-CSAL 
NSD-1015 and 
Acute 3-CSAL 
Chronic 3-CSAL 
1-CSAL t 
1-Carboxy-THP 
-+ f 
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Table 36 
A SUMMARY OF CARBOXYLATED-THIQs EFFECTS 
UPON STRIATAL 5-HT and 5-HIAA 
CONDITION 5-HT 5-HIAA 
ACUTE 3-CSAL 
30 Min. f _. 
1 Hr. f t 
+ 
_. 
3 Hr. 
8 Hr. + + 
24 Hr. ... t 
R04-4602 and t Acute 3-CSAL 
NSD-1015 and 
Acute 3-CSAL 
Chronic 3-CSAL 
1-CSAL t t 
1-Carboxy-THP + t 
Despite the fact that the alkaloids are structurally 
related to dopamine the carboxylated THIQs examined here 
have their most prominent effects on the serotonergic sys-
tem. The precise mechanisms underlying the elevations are 
not certain. 3-CSAL is not a good inhibitor of MAO A but it 
could be acting as a serotonin agonist or could be causing 
increases in the amount of "bound" 5-HT. 
Nevertheless, chronic 3-CSAL depletes the 5-HT content 
of both the hypothalamic and striatal tissues of rats. The 
nature of this deficit is unknown. It is possible that this 
is a neurotoxic effect. In support of this theory, Druse-
Manteuffel et at (140) have found that repeated injections 
of DNLCA (the 1-carboxy-THIQ condensation product of DA and 
phenylpyruvic acid), significantly reduced the striatal 5-HT 
content of rat pups. More experiments need to be designed to 
ascertain the mechanism of the 5-HT depletion and to deter-
mine if there is indeed a toxic effect of carboxylated-THIQs 
on the serotonergic system. 
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